This Article Extract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wigle, E. D. Articles by Williams, W. G. Search for Related Content PubMed PubMed Citation Articles by Wigle, E. D. Articles by Williams, W. G. Pubmed/NCBI databases Medline Plus Health Information Cardiomyopathy

(Circulation. 1995;92:1680-1692.)
© 1995 American Heart Association, Inc.

Articles

Hypertrophic Cardiomyopathy

Clinical Spectrum and Treatment

E. Douglas Wigle, MD; Harry Rakowski, MD; Brian P. Kimball, MD; William G. Williams, MD

From the Divisions of Cardiology and Cardiovascular Surgery and the Center for Cardiovascular Research, the Toronto Hospital, General Division, University of Toronto, Ontario, Canada.

Key Words: cardiomyopathy • cardiovascular diseases • myocardium • physiology • ventricles

	Introduction

Top Introduction Definition and Pathology Pathophysiology Clinical Spectrum Treatment HCM in the Elderly... Summary References

 
Although the pathology of HCM was described by two French pathologists in the mid 19th century^{1 2} and by a German pathologist in the early 20th century,³ it remained for the virtually simultaneous reports of Brock⁴ and Teare,⁵ some 37 years ago, to bring modern attention to this fascinating entity. Subsequent to these surgical⁴ and pathological⁵ observations, there has been an almost exponential growth in the number of research reports and in our knowledge of HCM, and a number of extensive reviews have been published.^{6 7 8 9 10 11} The growth in our knowledge of HCM parallels the development of various investigative techniques available to cardiology. Thus, the 1960s and 1970s were the clinical,^{12 13 14 15 16} hemodynamic,^{17 18 19 20 21 22 23 24 25 26 27 28 29} and angiographic^{30 31 32 33} era that focused mainly on obstructive HCM. The 1970s through the 1990s saw the various imaging modalities (echo-Doppler,^{34 35 36 37 38 39 40 41 42 43 44 45 46 47 48} nuclear,^{49 50 51 52 53 54} magnetic resonance,^{55 56 57 58} and positron emission tomography^{59 60} ) enhance our understanding of the systolic and diastolic abnormalities as well as the significance of myocardial ischemia in HCM. At the same time, electrophysiological techniques defined the spectrum of atrial and ventricular arrhythmias that are such an important feature of this disease.^{61 62 63 64 65}

More recently, the results of molecular genetic studies have resulted in a quantum leap in our basic knowledge and understanding of the mendelian dominant inheritance of HCM and have far-reaching prognostic and clinical implications.^{66 67 68 69 70 71 72 73 74 75 76 77 78 79 80} HCM is now described as a heterogeneous disease of the sarcomere,^{77 78} in that at least 34 missense mutations have been described in the ß-myosin heavy chain gene (chromosome 14q11-q12),^{66 67 68 69 70 71 72 75 76} 7 mutations have been described in cardiac troponin-T (chromosome 1),^{74 77 79} and 2 mutations in -tropomyosin (chromosome 15q2).^{77 78} Another locus has been found on chromosome 11p13-q13,⁷³ and familial HCM with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3.⁸⁰ The hypertrophy in HCM may be compensatory in response to the abnormalities induced by these mutations. This belief is supported by the upregulation of genes commonly observed in compensatory hypertrophy, ie, atrial and brain natriuretic peptides and angiotensin-converting enzyme.^{81 82 83 84 85 86} These molecular genetic studies are already having important clinical implications in that some mutations carry a benign prognosis,^{69 77} whereas others, possibly interacting with angiotensin-converting enzyme genotypes,^{85 86} have increased penetrance, early onset of manifestations, and a bad prognosis,^{69 77 79} thus explaining the malignant family history noted by some authors.⁸⁷

	Definition and Pathology

Top Introduction Definition and Pathology Pathophysiology Clinical Spectrum Treatment HCM in the Elderly... Summary References

 
Just as the inheritance of HCM is heterogeneous, so are the phenotypic manifestations, even in a single family cohort with the same molecular genetic defect⁷⁶ (Figs 1 through 3; Table 1). HCM may be defined as LV and/or RV hypertrophy of unknown cause that is usually, but not always, asymmetrical and associated with microscopic evidence of myocardial fiber disarray.^{7 8 9} Ventricular septal hypertrophy^{5 16} (Fig 1) is by far the most common type of asymmetrical hypertrophy, with midventricular^{8 88 89 90 91} (Fig 2), apical^{56 57 58 92 93 94} (Fig 3), and the rarer types⁴² of asymmetrical hypertrophy being far less common (Table 1). The extent of hypertrophy at any given site can vary greatly and bears importantly on the manifestations of the disease.⁸

View larger version (99K): [in this window] [in a new window]   Figure 1. Ventricular septal hypertrophy. Longitudinal section of the heart from a 32-year-old woman with subaortic obstructive HCM who died suddenly while on propranolol therapy. Hemodynamic investigation had confirmed the presence of subaortic obstruction, as well as mitral regurgitation that was partially due to an abnormal mitral valve (insertion of an anomalous papillary muscle [arrow] onto the ventricular surface of the anterior mitral leaflet). Note the asymmetric hypertrophy with a grossly thickened ventricular septum and a narrowed outflow tract between the upper septum and the anterior mitral leaflet, which is very thickened and fibrosed from repeated mitral leaflet–septal contact. There was microscopic evidence of extensive myocardial fiber disarray involving both the septum and the free wall of the left ventricle. From Wigle et al8 with permission.

View larger version (71K): [in this window] [in a new window]   Figure 2. Midventricular hypertrophy. Cross-sectional slices of the heart from a patient who in life was shown, by hemodynamic, angiographic, and echocardiographic techniques, to have midventricular obstruction. The site of the obstruction was at the level of the papillary muscles, where there was massive hypertrophy (second slice from left). The slice at left is from the base of the heart, and the two slices at the right are from the apex. The apex of the left ventricle was the site of extensive myocardial infarction and aneurysm formation that was evidenced in life by a dyskinetic apical chamber on angiography and by persistent ST segment elevation in leads V4 to V6 on the ECG. The coronary arteries revealed no significant luminal narrowings. The patient died of intractable ventricular arrhythmias. From Wigle et al8 with permission.

View larger version (91K): [in this window] [in a new window]   Figure 3. Apical hypertrophy. Magnetic resonance spin-echo images from a patient with apical HCM. A, Long-axis four-chamber slice demonstrates localized LV hypertrophy, involving the apical anterior and inferior walls, and the true apex (arrows). Note the characteristic spade-shaped left ventricular cavity at end diastole, described by Japanese authors92 93 and caused by the anterior and inferior wall apical hypertrophy. B, Short-axis basal slice showing normal LV wall thickness. C, Short-axis apical slice demonstrating circumferential apical hypertrophy. Recently, a non–spade-shaped variety of apical HCM has been described, again by Japanese authors,56 and in these cases, the anterior and inferior apical walls are not involved as they are in A, but rather the septal and lateral walls are involved, and this can only be picked up by short-axis MRI scanning, as seen in C. From Webb et al57 with permission.

View this table: [in this window] [in a new window]   Table 1. Types of HCM and Approximate Incidence1

	Pathophysiology

Top Introduction Definition and Pathology Pathophysiology Clinical Spectrum Treatment HCM in the Elderly... Summary References

 
The following is a description of the clinically important pathophysiological features of HCM that bear upon the clinical spectrum and treatment.

Obstruction to LV Outflow
Subaortic Obstruction
The pathology of the subaortic obstruction in HCM is shown in Fig 1. The pathophysiology of the obstruction and mitral regurgitation in subaortic obstructive HCM is shown in Fig 4, and the transesophageal echocardiographic–color Doppler appearance of these features⁴⁸ is shown in Fig 5. It is believed that the narrow LV outflow tract, caused by the ventricular septal hypertrophy and the anterior displacement of the papillary muscles^{38 95} and mitral leaflets,^{36 39 45 95 96 97} is important to the development of the obstruction, as is the fact that the mitral leaflets are elongated^{45 48 95 96 97} and coapt in the body of the leaflets,^{45 48 95} rather than at their tips, as is normal.⁴⁵ That part of the anterior leaflet distal to the coaptation point is subjected to Venturi²⁹ and/or drag^{8 36 98 99} forces, resulting in systolic anterior motion^{34 45 48} and subsequent mitral leaflet–septal contact,⁸ causing the subaortic obstruction^{34 35 36 37 38 39 40 41} (Figs 4 and 5). The systolic anterior motion of the anterior mitral leaflet also results in a failure of coaptation of the mitral leaflets,⁴⁸ and it is through this funnel-shaped interleaflet gap that the mitral regurgitation is directed posteriorly into the left atrium⁴⁸ (Figs 4 and 5).

View larger version (37K): [in this window] [in a new window]   Figure 4. Diagram of pathophysiology of the obstruction to outflow and mitral regurgitation in subaortic obstructive HCM. Early systole (left): The left ventricular outflow tract is narrowed by the ventricular septal hypertrophy and the anterior displacement of the papillary muscles38 39 and the mitral leaflets.36 39 45 95 96 97 The point of coaptation of the elongated mitral leaflets occurs in the body of the leaflets, rather than at the tips, as is normal.45 48 95 That part of the anterior leaflet beyond the coaptation point45 48 is carried anteriorly and superiorly (systolic anterior motion, arrow) by Venturi29 and/or drag35 36 98 99 forces and results in mitral leaflet–septal contact, causing the subaortic obstruction (indicated by the converging and diverging lines, right). Mitral leaflet–septal contact (right): The systolic anterior motion of the anterior leaflet results in a failure of coaptation of the mitral leaflets48 and the onset of mitral regurgitation, which is directed posteriorly into the left atrium, through the funnel-shaped interleaflet gap. The length and mobility of the posterior leaflet may also affect the size of this gap, and hence the degree of mitral regurgitation.102 A, B, C, and D indicate Doppler velocity recordings throughout systole in the ascending aorta103 (A) (flow toward transducer), at level of mitral leaflet–septal contact46 (B), in left atrium (C), and near apex of LV (D). In B, C, and D, flow is away from the transducer. Reduced forward flow in the presence of the obstruction is indicated by the shape of the aortic velocity waveform103 (A) and the smaller aortic arrow. Peak velocities recorded at B correlate accurately with the simultaneously measured pressure gradient,46 whereas late-peaking velocities at D do not. AO indicates aorta; MV, mitral valve. Adapted from Wigle10 with permission.

View larger version (0K): [in this window] [in a new window]   Figure 5. Intraoperative transesophageal echocardiogram (frontal long-axis plane) before (top) and after (bottom) myectomy. Upper left, Two-dimensional systolic frame demonstrating anterior leaflet–septal contact with failure of mitral leaflet coaptation. Upper right, same frame with Doppler color flow imaging demonstrating turbulent LV outflow as a result of the subaortic obstruction and a large jet of posteriorly directed mitral regurgitation arising from the gap between the two leaflets. Lower left, two-dimensional systolic frame demonstrating a widened LV outflow tract and abolition of systolic anterior motion following myectomy. Lower right, same frame with Doppler color flow imaging demonstrating nonturbulent LV outflow with a marked reduction in the severity of the mitral regurgitation, which is now reflected only by a small residual central jet. From Grigg et al48 with permission.

The onset of the pressure gradient is virtually simultaneous with the onset of mitral leaflet–septal contact.^{40 41} The time of onset and duration of mitral leaflet–septal contact in systole determines the magnitude of the pressure gradient^{8 40 41} and the degree of prolongation of the LV ejection time^{8 40 41 100 101} ; ie, the pressure gradient and ejection time become progressively greater as the time of mitral leaflet–septal contact occurs earlier in systole.

When there is no additional mitral valve abnormality other than systolic anterior motion, there is a direct relation between the magnitude of the pressure gradient and the degree of mitral regurgitation.^{8 26 27} The fact that there is leaflet coaptation in early systole and that systolic anterior motion results in a failure of coaptation of the leaflets by midsystole⁴⁸ explains the mid- to late-systolic timing of the mitral regurgitation in subaortic obstructive HCM. It also explains the eject/obstruct/leak sequence of events in systole, described from cineangiographic observations, in which there is rapid early ejection into the aorta, followed by the radiolucent line indicating the subaortic obstruction, followed by mid- to late-systolic mitral regurgitation.^{8 32} Thus, the time of onset and duration of mitral leaflet–septal contact determines not only the magnitude of the pressure gradient and the degree of prolongation of the LV ejection time but also the degree of mitral regurgitation and the volume of blood ejected from the left ventricle in the presence of obstruction.⁸

In about 20% of patients with subaortic obstruction in HCM, the mitral regurgitation is to a variable extent independent of the systolic anterior motion,^{8 27} in which case, other abnormalities of the mitral valve are present, such as anomalous papillary muscle attachment to the anterior leaflet^{8 27 104} (Fig 1), mitral valve prolapse,¹⁰⁵ extensive anterior leaflet fibrosis due to repeated mitral leaflet–septal contact^{8 97} (Fig 1), mitral annular calcification, or other rarer abnormalities. These independent abnormalities of the mitral valve at times cause pansystolic mitral regurgitation, which is often anteriorly or centrally directed into the left atrium and is quite different from the late-onset, posteriorly directed mitral regurgitation that is the result of anterior mitral leaflet systolic anterior motion.⁴⁸

Although several exercise studies with subjects in the supine position have reported no increase in gradient during exercise, but only afterward,^{6 106} a recent study reported a 50% increase in gradient during supine exercise, as well as revealing latent obstruction in 30% of patients who had no obstruction at rest.¹⁰⁷ Even more significant is the fact that on upright bicycle exercise, the magnitude of the pressure gradient almost doubled.¹⁰⁸ These observations are very much in keeping with the factors known to affect the severity of the obstruction^{6 8 9} (LV contractility, afterload, and preload) and suggest caution in the interpretation of exercise studies involving patients with or without obstruction under control conditions unless the presence and magnitude of the obstruction during exercise are known. The increased gradient on upright exercise is also very much in keeping with the severity of symptoms observed in some patients with subaortic obstructive HCM on exertion and the ease with which symptoms may sometimes occur with minor exercise after the upright posture is assumed or postprandially.¹⁰⁹

Midventricular Obstruction
The pathology of midventricular obstruction is depicted in Fig 2, which clearly demonstrates that the obstruction is at the papillary muscle level.^{8 88 89 90 91} Apical myocardial infarction in the presence of large normal coronary arteries is not uncommon with midventricular obstruction,^{8 90 91} as is the case in apical HCM.⁵⁷ The syndrome of midventricular obstruction with apical infarction may evolve by two mechanisms: (1) apical infarction may occur in the presence of midventricular obstruction or (2) apical infarction may occur in severe apical HCM with cavity obliteration up to the midventricular level, in which case the noninfarcted proximal part of the apical hypertrophy at the midventricular level results in the midventricular obstruction.^{8 90 91} The severity of the midventricular obstruction is affected by LV contractility, afterload, and preload, as is the case with subaortic obstruction.⁸ Angiographically, midventricular obstruction is best recognized in the right anterior oblique LV cineangiogram,^{88 89 90 91} in contrast to the subaortic obstruction, whose dynamics are best appreciated in the left anterior oblique LV cineangiogram with cranial angulation.^{8 32} The size of the obstructed apical chamber in midventricular obstruction may vary considerably, but it is always smaller than the amount of the LV cavity that is obstructed in the subaortic obstruction (Fig 6). In contrast to the subaortic obstruction in HCM, mitral regurgitation is not a feature of midventricular obstruction. There are a number of other differences between these two forms of obstructive HCM⁸ (Fig 6).

View larger version (27K): [in this window] [in a new window]   Figure 6. Diagram showing LV inflow tract pressure concept.25 In subaortic obstructive HCM, all LV pressures proximal to the outflow tract obstruction caused by mitral leaflet–septal contact (arrow) are elevated, including the inflow tract pressure, just inside the mitral valve. In cavity obliteration and midventricular obstruction, the pressure at the apex of the LV is elevated, but the inflow tract pressure is not. Note that the amount of the LV cavity that is obstructed in subaortic obstructive HCM is greater than in midventricular obstruction (see text). AO indicates aorta. Adapted from Wigle10 with permission.

Systolic Dysfunction
LV systolic function in HCM is usually normal to supranormal, with a high ejection fraction, in both obstructive and nonobstructive forms of the disease. Late in the disease, however, impaired systolic function of both the LV and RV caused by myocardial fibrosis has been recognized with increased frequency (end-stage HCM).^{110 111 112 113} The fibrosis^{114 115} may occur as the result of fibrous transformation of the loose intercellular connective tissue that is interspersed between areas of myocardial fiber disarray^{5 8} or as a result of myocardial ischemia and infarction due to small-vessel disease^{112 116} or rarely, as a result of concomitant atherosclerotic coronary artery disease. This myocardial fibrosis results in wall thinning, loss of outflow obstruction, incoordinate and impaired systolic function with reduced ejection fraction, and increased end-systolic volume.^{110 111 112 113} There is moderate ventricular dilatation, but this is usually less than in typical dilated cardiomyopathy.

Diastolic Dysfunction
Initially, diastolic dysfunction in HCM was felt to be due to decreased ventricular compliance (increased chamber stiffness),^{13 16} but with enhanced understanding of diastole,^{117 118 119} it has become evident that impaired relaxation is the more important cause of diastolic dysfunction in HCM.^{8 120} Fig 7 depicts the way that HCM can affect ventricular diastolic filling.⁸ Chamber stiffness is increased (compliance decreased) by virtue of the increase in muscle mass, decrease in ventricular volume, and increase in muscle stiffness caused by myocardial fibrosis. This increased chamber stiffness results in an increased diastolic pressure with respect to volume (increased dP/dv), ie, the diastolic pressure-volume curve is shifted upward and to the left.¹²¹

View larger version (22K): [in this window] [in a new window]   Figure 7. Diagram indicating the mechanisms by which chamber stiffness is increased and relaxation is impaired in HCM. In some patients with extensive hypertrophy, increased restoring forces may act to improve relaxation during isovolumic relaxation, whereas the degree of pericardial constraint and ventricular interaction may be decreased by the extent of septal hypertrophy8 (see text). Adapted from Wigle et al8 with permission.

Ventricular relaxation is related to certain hemodynamic loads (both systolic and diastolic), to inactivation (the reuptake of calcium by the sarcoplasmic reticulum), and to the degree of nonuniformity of load and inactivation in space and time.^{117 118 119} Normally, relaxation is load dependent.^{117 118} In HCM, relaxation may be impaired by the systolic contraction load (the obstruction to outflow⁸ ) and perhaps more importantly, by the reduced relaxation loads (ventricular filling and coronary filling loads^{117 118 119} ) (Fig 7). Inactivation may be impaired by the increased myoplasmic calcium that has been reported in HCM.^{122 123} This alone would impair relaxation, but diminished inactivation would also reduce the load dependence of relaxation,^{117 118 119} and the loads are already reduced⁸ (the double-edged sword effect of impaired inactivation^{117 118 119} ). Finally, there is ample evidence that nonuniformity contributes to the impaired relaxation in HCM.^{124 125 126} Thus, all three factors that regulate ventricular relaxation are altered in HCM in a way that would impair relaxation.

Impaired relaxation in HCM results in a reduced rate and volume of filling during the rapid filling period of diastole, with a resultant compensatory increase in atrial systolic filling, which results in a loud and often palpable fourth heart sound.* Patients with HCM and impaired relaxation, including patients with apical HCM,⁵⁷ develop progressive LA enlargement and atrial fibrillation, which results in severe hemodynamic deterioration because of the importance of atrial systole in the presence of impaired relaxation.^{8 10 49 50 51 120 127} Late in the evolution of diastolic dysfunction, a restrictive type of diastolic filling defect may become evident⁴⁴ in which a high atrial pressure results in an increased rate and volume of filling during the rapid filling period (loud third heart sound^{10 120} ) with reduced filling during atrial systole.⁴⁴

Myocardial Ischemia
Myocardial ischemia has been repeatedly demonstrated in both obstructive and nonobstructive HCM by means of fixed and reversible thallium perfusion defects^{52 53 54} ; by measurement of myocardial lactate production, particularly during rapid atrial pacing^{129 130 131} ; and by positron emission tomography.^{59 60} Although the exact cause of the ischemia is in some doubt, it may be related to small-vessel disease with decreased vasodilator capacity.^{116 129} Other factors that could cause or contribute to ischemia are septal perforator artery compression,⁸ myocardial bridging,⁸ decreased coronary perfusion pressure,¹²⁹ obstruction to LV outflow,^{8 30} and decreased capillary myocardial fiber ratio. Impaired relaxation of the myocardium during the isovolumic and rapid filling periods could impair coronary filling and result in ischemia.⁸ On the other hand, myocardial ischemia could act to impair relaxation by a number of mechanisms. Indeed, a vicious cycle may exist in HCM that relates diminished coronary perfusion and myocardial ischemia with impaired diastolic relaxation and vice versa.⁸

	Clinical Spectrum

Top Introduction Definition and Pathology Pathophysiology Clinical Spectrum Treatment HCM in the Elderly... Summary References

 
As a result of the above considerations, it is customary to classify HCM hemodynamically as in Table 2. In obstructive HCM, the subaortic or midventricular obstruction may be latent (provocable), labile (spontaneously variable), or persistent (obstruction at rest). In nonobstructive HCM, there is no systolic obstruction at rest or on provocation.⁸

View this table: [in this window] [in a new window]   Table 2. Hemodynamic Classification of HCM

Symptoms
Patients with obstructive HCM typically complain of dyspnea, angina, and presyncope and/or syncope on exertion. The severity of symptoms on upright exertion does not necessarily correlate with the magnitude of the obstructive pressure gradient measured in the supine position, which is understandable, particularly when the lability of the obstruction is taken into account.^{6 8 9 107 108} In our experience, patients with nonobstructive HCM present with these symptoms less frequently, and usually the symptoms are milder.⁸ Congestive heart failure is rarely seen in HCM in normal sinus rhythm, but it may be seen with severe obstruction to outflow or severe systolic and/or diastolic dysfunction, and of course it is common in the presence of atrial fibrillation.

Physical Examination
RV involvement in HCM may be detected by a prominent A wave in the jugular venous pulse and rarely by a right-sided fourth heart sound, reflecting RV diastolic dysfunction, and by a systolic ejection murmur along the left sternal border, reflecting subpulmonic or midventricular obstruction to RV outflow.^{8 16}

LV involvement is reflected by a variably displaced and forceful LV impulse and a left-sided fourth heart sound that is often palpable,^{13 16} reflecting impaired LV relaxation.^{10 49 120} Patients with nonobstructive HCM have either no murmur or a faint grade 1/6 systolic murmur at the cardiac apex that does not increase significantly with provocation.⁸ In patients with latent subaortic obstruction, the murmur at the apex is usually grade 1/6 to 2/6 in intensity and increases to grade 3/6 with appropriate provocation,⁸ such as amyl nitrite inhalation,¹⁸ assuming the upright posture, or the Valsalva maneuver.⁶ In patients with subaortic obstructive HCM at rest, the murmur at or just medial to the apex is grade 3/6 to 4/6 in intensity, with radiation to the left sternal border, reflecting the obstruction, and to the axilla, reflecting the mitral regurgitation. In addition to the louder murmur, there is an intriguing constellation of physical signs in subaortic obstructive HCM not seen in nonobstructive HCM. These include a bifid arterial pulse,¹³² a double systolic or triple apex beat,¹³³ reversed splitting of the second heart sound, a mitral diastolic inflow murmur due to mitral regurgitation,⁸ and rarely a mitral leaflet–septal contact sound.⁸

Patients with midventricular obstruction also have an apical systolic murmur, although it is usually softer (grade 2/6 to 3/6) than with subaortic obstruction. A bifid arterial pulse, double systolic beat, and triple apex beat are not characteristic of midventricular obstruction, and a mitral leaflet–septal contact sound is never found. If the obstruction is severe, there may be reversed splitting of the second heart sound. In midventricular obstruction, there is at times a very distinctive, long, mitral diastolic murmur caused by the midventricular narrowing and asynchronous relaxation.

Clinical Course
The clinical course of HCM is very variable (some would say unpredictable). Although the rate of progression of the disease is believed to be more rapid in children, adolescents (particularly during the teenage growth years⁴³ ), and young adults, rapid progression may also be encountered in the adult population of patients. The best predictor of outcome may turn out to be the nature of the molecular genetic defect^{69 77 79} ; at present, the risk factors for sudden death are considered to be young age,^{134 135 136 137 138} syncope,^{135 137 138 139} a malignant family history,⁸⁷ myocardial ischemia (particularly in the young),⁵⁴ sustained ventricular tachycardia on electrophysiological testing,⁶³ and ventricular tachycardia on ambulatory monitoring.^{61 62} More recent studies suggest that ventricular tachycardia on ambulatory monitoring is more benign¹⁴⁰ unless associated with altered consciousness or sustained ventricular tachycardia on electrophysiological testing.⁶³ The fact that unexplained syncope and cardiac arrest in obstructive HCM can be satisfactorily managed by alleviation or abolition of the obstruction by dual-chamber pacing¹⁴¹ or myectomy¹⁴² suggests that outflow obstruction is also a risk factor for sudden death.

Syncope in HCM may be related to atrial or ventricular tachyarrhythmias or bradyarrhythmias,¹³⁹ heart block,¹³⁹ obstruction to LV outflow,¹⁴³ diastolic dysfunction, altered baroreflex mechanisms,^{144 145} and myocardial ischemia.⁵⁴ Unfortunately, many studies concerned with syncope in HCM do not distinguish whether it occurred at rest or on exertion, and the presumption is that it was arrhythmic in origin. In our experience, presyncope and syncope on exertion are encountered most frequently in patients with obstructive HCM, and at times the degree of exertion required to bring on profound presyncope or syncope may be minimal.

The annual mortality in HCM referral centers is said to be 4% to 6% in children and 3% to 4% in adults.^{138 146} However, recent studies from a community-based experience¹⁴⁷ as well as from a tertiary referral center¹⁴⁸ have indicated an annual mortality of 1%. HCM is the most common cause of unexplained sudden death in otherwise apparently healthy competitive athletes.¹⁴⁹

Laboratory Investigation
Patients referred with suspected HCM should have an ECG, a chest x-ray, and a transthoracic echo/Doppler examination on the initial visit.

The ECG in HCM may be normal with mild degrees of hypertrophy or show LV hypertrophy and strain in the presence of extensive hypertrophy.⁸ Abnormal Q waves, which may mimic myocardial infarction and which at times reflect septal hypertrophy,¹⁵⁰ are a feature of the ECG in HCM, as is the giant T-negativity syndrome typical of apical HCM.^{92 93} Apical infarction may also be reflected in the ECG,⁵⁷ and the ECG may be abnormal in HCM when echocardiography reveals no evidence of LV hypertrophy.¹⁵¹

The chest x-ray may be normal or show LV or LA and/or RA enlargement with or without vascular redistribution in the lungs. The aorta is typically small. A bulge on the left heart border, between the LA appendage and LV apex, may reflect anterolateral wall extension of anteroseptal hypertrophy.¹³³

Transthoracic echo/Doppler examination in HCM is undoubtedly the most important form of laboratory investigation. These combined techniques can determine the location and extent of hypertrophy,^{8 42 152} systolic^{111 112 113} and diastolic function,^{44 46 47} the presence and degree of systolic anterior motion,^{34 35 36 37 38 39 40 41} the severity of the subaortic and/or midventricular obstruction,^{35 36 39 40 41 46 47} the direction and degree of mitral regurgitation,^{46 47 48} the presence of additional mitral valve abnormalities,^{104 105} and LA size. Transesophageal echo/Doppler studies are valuable in defining additional mitral valve abnormalities and the level of outflow obstruction and are used intraoperatively in planning, guiding, and assessing the results of surgical intervention.^{48 153}

Nuclear angiography is very valuable in HCM to assess both systolic and diastolic ventricular function.^{49 50 51} Stress thallium studies^{52 53 54} and positron emission tomography^{59 60} are important for detecting evidence of myocardial ischemia or infarction.

Magnetic resonance imaging is of particular value in HCM when two-dimensional echocardiography is unable to document the site and extent of hypertrophy, especially in apical HCM^{55 56 57 58} (Fig 3).

Heart catheterization and angiography in HCM are usually reserved for diagnostic problems, when surgery or dual-chamber pacing is being considered in either type of obstructive HCM, and in the investigation of end-stage HCM in regard to the possibility of cardiac transplantation. The diagnostic accuracy of echo/Doppler studies has dramatically lessened the need for invasive investigation in HCM.

Electrophysiological investigation has traditionally used ambulatory monitoring for detection and assessment of treatment of all arrhythmias in HCM, particularly ventricular arrhythmias.^{61 62 63 140} More recently, invasive electrophysiological studies have been used extensively in some centers to provoke arrhythmias as a guide to prog-nosis and therapy.⁶³

Genetic screening for HCM is prognostically important and undoubtedly will become more common once all the molecular genetic defects are defined and screening procedures simplified.

	Treatment

Top Introduction Definition and Pathology Pathophysiology Clinical Spectrum Treatment HCM in the Elderly... Summary References

 
The treatment of HCM should be based on the patient's symptoms and on whether the patient has obstructive or nonobstructive disease. The presence of other pathophysiological abnormalities, such as myocardial ischemia, impaired systolic and/or diastolic function, arrhythmias, syncope, and a history of cardiac arrest, should also be taken into consideration. The role of treatment for the asymptomatic patient has not been clearly defined, and the decision to treat or not to treat any given patient should be based on the presence or absence of a malignant family history, the nature of the molecular genetic defect if known, and the severity of the pathophysiological abnormalities present.

Obstructive HCM
The treatment of subaortic and midventricular obstructive HCM is basically the same, although the effects of medical, pacemaker, and surgical therapy have been much better documented in subaortic obstructive HCM.

Medical Therapy
In obstructive HCM, negative inotropic agents (ß-blockers,^{154 155 156 157 158 159 160 161 162} calcium antagonists,^{49 50 163 164 165 166 167 168} and disopyramide^{8 169 170 171 172} ) have been used to decrease the degree of outflow obstruction. In our experience, ß-blockers are especially effective in latent obstruction and to some extent in mild resting obstruction but tend to be less effective in the more severe degrees of obstruction,^{8 159} although others have reported more favorable results.^{154 155 156 158 160} The negative inotropic properties of calcium antagonists, particularly verapamil, usually lessen the obstruction,^{163 164 165 166 167 168} but unpredictably, the vasodilating properties of these drugs may increase the obstruction, with resultant death due to intensified obstruction, cardiogenic shock, and pulmonary edema.¹⁶⁷ It is for this reason that we have avoided the use of calcium antagonists, particularly those with potent vasodilating properties, in obstructive HCM.⁸ The negative inotropic effect of the type 1A antiarrhythmic agent disopyramide has been demonstrated to decrease or abolish the obstruction when given intravenously^{8 169 170 172} or in oral doses up to 600 to 800 mg/d.^{8 169 171} This drug has the disadvantage of having a number of anticholinergic side effects, and in a significant percentage of patients, the initial clinical and hemodynamic benefits decrease with time. Despite these problems, at present, it is our drug of choice in treating symptomatic obstructive HCM.⁸ If the resting heart rate is >70 beats per minute, we would add a ß-blocker to slow the rate to 60 to 65 beats per minute.⁸

Pacemaker Therapy
Dual-chamber (DDD) pacing has been recognized for almost 20 years to decrease the subaortic pressure gradient in HCM, but only recently has it been extensively studied and used.^{173 174 175 176 177 178 179} The mechanism by which the gradient is decreased is uncertain but may be related to decreased (or paradoxical) septal motion,^{177 178} late activation at the base of the septum with RV apical pacing,¹⁸⁰ or decreased LV contractility.¹⁷⁸ There is a progressive reduction in the gradient with time¹⁷⁸ and a short-term persistence of pacing effect in normal sinus rhythm,¹⁷⁷ suggesting the possibility of LV remodeling or a mechanical memory effect. Acute studies reveal impairment of both systolic and diastolic function, possibly related to asynchronous contraction and relaxation.^{181 182} To be successful, there must be complete ventricular capture, which requires optimization of the AV delay.^{177 178 179} This is readily accomplished in patients with a PR interval of 120 to 180 ms, but when the PR interval is shorter, a very short AV delay (50 to 60 ms) is frequently required for complete ventricular capture.¹⁸³ This often results in significant diastolic dysfunction with a loss of effective LA function. It is in this group of patients that drugs (ß-blockers, calcium antagonists) must be given to prolong the PR interval or AV nodal ablation is required to avoid the deleterious effects of a very short AV delay.¹⁸³ To have complete ventricular capture at all times (which is required for successful therapy), there should be separate programming of the paced and sensed AV delay and an autoadaptive function to shorten AV delay with increased heart rates.¹⁸⁴

There are now numerous reports of significant symptomatic improvement with dual-chamber pacing in patients with obstructive HCM refractory to medical therapy.^{176 177 178 183} Thus, dual-chamber pacing in obstructive HCM represents a viable alternative to myectomy surgery, particularly if a low-risk and effective surgical program is not readily available.¹⁷⁹ Dual-chamber pacing may have a particular role to play in elderly patients, in whom the PR interval tends to be longer and who are unresponsive to medical therapy, yet have severe symptomatic obstruction and are often poor candidates for open-heart surgery. It is important to note, however, that not all patients with obstructive HCM respond favorably to dual-chamber pacing and that the long-term effects of this treatment modality are currently unknown.

Surgical Therapy
Myectomy surgery for symptomatic obstructive HCM that is unresponsive to medical therapy has been carried out successfully for more than three decades.^{185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201} In our experience, successful surgery (total relief of the obstruction at rest and on provocation) provides far more hemodynamic and symptomatic benefits for severely symptomatic patients than any form of medical therapy currently available.^{8 188 196 200} The occurrence of atrial fibrillation is also an indication for myectomy, in that abolition of the obstruction and the concomitant mitral regurgitation can result in a decrease in LA size in younger patients, which is the most effective form of antiarrhythmic therapy for these individuals.^{8 202 203} Similarly, patients with obstructive HCM who have suffered unexplained syncope or cardiac arrest have been managed successfully by myectomy alone.¹⁴² Although the annual mortality of obstructive HCM has been reported to be 3% to 4%,¹⁴⁶ several large surgical series have reported postoperative annual mortality rates of 1% to 2%.^{191 192 193 196 199 200}

Several centers have carried out mitral valve replacement as either the primary surgical intervention²⁰¹ or in a significant percentage of their patient population.¹⁹⁵ This procedure removes the offending mitral leaflets but condemns the patient to a low-profile mechanical prosthesis and lifelong anticoagulants. We have rarely replaced a mitral valve in these patients, and only when there is a significant independent abnormality of the mitral valve, causing severe mitral regurgitation, that is not related to the systolic anterior motion.^{8 159 188 189 196 200} A number of centers have reported mortality rates of <2% for the myectomy operation alone, with somewhat higher mortality rates when combined with valve replacement or bypass surgery.^{193 196 197 199 200} Myectomy thins the ventricular septum and widens the outflow tract, which results in abolition of the systolic anterior motion, with resultant relief of the outflow obstruction and the concomitant mitral regurgitation.^{8 10} LV end-diastolic and LA pressures decrease,¹⁸⁸ with a resultant decrease in LA size in patients <45 years of age.^{8 203}

Dual-Chamber Pacing Versus Myectomy
Thus far, there has been no direct comparison between these two treatment modalities, both of which appear to be superior to medical therapy. In the absence of experienced, effective, and low-risk surgery, dual-chamber pacing is a viable alternative, but it does not appear to totally abolish the obstruction as effectively as successful surgery.^{177 178 179} In addition, the long-term effects of pacemaker therapy in obstructive HCM are unknown. We continue to offer the myectomy operation to symptomatic patients who are refractory to medical therapy, because of the presence of an experienced, effective, and low-risk surgical program,^{196 200} but we are also assessing the effects of dual-chamber pacing where appropriate.

Nonobstructive HCM
Normal Systolic Function
Calcium antagonists are the preferred therapy for nonobstructive HCM with normal systolic function and impaired relaxation and/or myocardial ischemia.^{49 50 51 54 163 164 165 166 167 168} If calcium antagonists are not tolerated, slowing of the heart rate with ß-adrenergic blockers will act to relieve ischemia and will allow more time for relaxation during diastole.

Impaired Systolic Function
Table 3 contrasts the diametrically opposite therapy for nonobstructive HCM with impaired systolic function (end-stage HCM) versus therapy for obstructive HCM. In the latter, digitalis, afterload reduction, and diuretics are contraindicated because they could worsen the obstruction and negative inotropes are indicated to lessen the obstruction. In nonobstructive HCM with impaired systolic function and no outflow obstruction, digitalis, afterload reduction, and diuretics are indicated and negative inotropes contraindicated to improve systolic function (Table 3). In obstructive HCM, dual-chamber pacing or myectomy surgery is indicated in patients refractory to medical therapy. In nonobstructive HCM with impaired systolic function, pacemaker therapy is indicated only for electrophysiological reasons, and transplantation is the only surgical treatment that is appropriate.

View this table: [in this window] [in a new window]   Table 3. Treatment of Obstructive HCM Versus Nonobstructive HCM With Impaired Systolic Function (End-Stage HCM)

Arrhythmias
Atrial Fibrillation
Atrial fibrillation in the vast majority of cases of HCM is related to an increase in LA size (usually >50 mm).^{8 202} Obstructive HCM with concomitant mitral regurgitation is the most common cause of increased LA size and atrial fibrillation,^{8 39 203} but both systolic and diastolic dysfunction may also lead to significant LA enlargement and atrial arrhythmias.⁵⁷ The onset of atrial fibrillation in both obstructive and nonobstructive HCM may result in cardiac failure, syncope, and systemic emboli.⁸ Management is similar to that in other cardiac diseases with this arrhythmia and includes pharmacological and electrical cardioversion, therapy for congestive heart failure, and anticoagulation. Amiodarone is the most effective pharmacological agent to restore and maintain normal sinus rhythm in HCM,²⁰⁴ but because of its side effects and the fact that we are usually dealing with a young patient population, we have tended to use other antiarrhythmic agents, such as sotalol, first. Patients with obstructive HCM and atrial fibrillation are candidates for myectomy to reduce LA size and thereby restore normal sinus rhythm by this mechanism.^{8 203}

Ventricular Tachycardia and Fibrillation
There is no universally accepted therapy for ventricular tachycardia and/or fibrillation in patients with HCM.¹³⁸ Patients with obstructive HCM and unexplained syncope, cardiac arrest, and ventricular tachycardia and/or fibrillation have been treated successfully by dual-chamber pacing¹⁴¹ or myectomy¹⁴² alone. Alternatively, these interventions could be combined with amiodarone therapy or an AICD.⁶³ Patients with nonobstructive HCM and a history of cardiac arrest or unexplained syncope may undergo electrophysiological testing and be treated with amiodarone or an AICD if test findings are positive.⁶³ Younger HCM patients who have a history of cardiac arrest and/or syncope but who are electrophysiologically negative should undergo stress thallium testing for myocardial ischemia, which, if present, should be treated with calcium antagonists or ß-blockers, with or without amiodarone or an AICD.⁵⁴ Cardiac transplantation has been performed in a few patients with life-threatening refractory ventricular tachycardia or fibrillation.

	HCM in the Elderly

Top Introduction Definition and Pathology Pathophysiology Clinical Spectrum Treatment HCM in the Elderly... Summary References

 
It is important to recognize that older patients with or without a past history of hypertension may present with a clinical picture resembling that seen in genetically determined HCM, including obstruction to outflow.^{205 206 207 208 209} In some of these older patients, the disease may be more related to hypertensive hypertrophy²⁰⁵ or to age-related changes such as a sigmoid septum²⁰⁶ and/or mitral annular calcification,²⁰⁷ rather than to HCM per se. The principles of treatment for these patients are the same as for HCM.

	Summary

Top Introduction Definition and Pathology Pathophysiology Clinical Spectrum Treatment HCM in the Elderly... Summary References

 
HCM is a heterogeneous disease genotypically, phenotypically, pathophysiologically, clinically, and therapeutically. In decisions on the management of these patients, it is important to recognize this heterogeneity and to direct therapy at the predominant abnormalities.

	Selected Abbreviations and Acronyms

 

AICD = automatic implantable cardioverter/defibrillator AV = atrioventricular HCM = hypertrophic cardiomyopathy LA = left atrial LV = left ventricular RV = right ventricular

	Acknowledgments

 
The authors wish to thank Sharon Tribble for her excellent technical assistance in preparing the manuscript.

	Footnotes

 
Reprint requests to E. Douglas Wigle, MD, 12-217 Eaton North, Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, Canada, M5G 2C4.

¹ References 10, 44, 46, 47, 49-51, 120, 127, 128

Received November 28, 1994; revision received May 31, 1995; accepted June 13, 1995.

	References

Top Introduction Definition and Pathology Pathophysiology Clinical Spectrum Treatment HCM in the Elderly... Summary References

 
1. Liouville H. Rétrécissement cardiaque sous aortique. Gaz Med Paris. 1869;24:161-163.

2. Hallopeau L. Rétrécissement ventriculo-aortique. Gaz Med Paris. 1869;24:683-684.

3. Schmincke A. Ueber linksseitige muskulose Conusstenosen. Dtsch Med Wochenschr. 1907;33:2082.

4. Brock RC. Functional obstruction of the left ventricle. Guys Hosp Rep. 1957;106:221-238. [Medline] [Order article via Infotrieve]

5. Teare RD. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1-8.

6. Braunwald E, Lambrew C, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis, I: description of the disease based upon an analysis of 64 patients. Circulation. 1964;29(suppl IV):IV-3-IV-119.

7. Goodwin JF. The frontiers of cardiomyopathy. Br Heart J. 1982;48:1-18. [Free Full Text]

8. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis. 1985;28:1-83. [Medline] [Order article via Infotrieve]

9. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316:780-789, 844-852. [Medline] [Order article via Infotrieve]

10. Wigle ED. Hypertrophic cardiomyopathy: a 1987 viewpoint. Circulation. 1987;75:311-322. Editorial. [Free Full Text]

11. Maron BJ. Hypertrophic cardiomyopathy. Current Prob Cardiol. 1993;642-693.

12. Bercu BA, Diettert GA, Danforth WH, Pund EE Jr, Ahlvin RC, Belliveau RR. Pseudoaortic stenosis produced by ventricular hypertrophy. Am J Med. 1958;25:814-818. [Medline] [Order article via Infotrieve]

13. Braunwald E, Morrow AG, Cornell WP, Aygen MM, Hilbish TF. Idiopathic hypertrophic subaortic stenosis. Am J Med. 1960;29:924-945.

14. Goodwin JF, Hollman A, Cleland WP, Teare D. Obstructive cardiomyopathy simulating aortic stenosis. Br Heart J. 1960;22:403-414.

15. Menges H Jr, Brandenburg RO, Brown AL Jr. The clinical, hemodynamic and pathologic diagnosis of muscular subvalvular aortic stenosis. Circulation. 1961;24:1126-1136. [Abstract/Free Full Text]

16. Wigle ED, Heimbecker RO, Gunton RW. Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. Circulation. 1962;26:325-340. [Abstract/Free Full Text]

17. Braunwald E, Ebert P. Hemodynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. Am J Cardiol. 1962;10:489-495. [Medline] [Order article via Infotrieve]

18. Wigle ED, Lenkei S, Chrysohou A, Wilson DR. Muscular subaortic stenosis: the effect of peripheral vasodilation. Can Med Assoc J. 1963;89:896-899.

19. Pierce GE, Morrow AG, Braunwald E. Idiopathic hypertrophic subaortic stenosis, III: intraoperative studies of the mechanism of obstruction and its hemodynamic consequences. Circulation. 1964;30(suppl IV):IV-152-IV-213.

20. Hernandez RR, Greenfield JC Jr, McCall BW. Pressure-flow studies in hypertrophic subaortic stenosis. J Clin Invest. 1964;43:401-407.

21. Whalen RE, Cohen AI, Summer RG, McIntosh HD. Demonstration of the dynamic nature of idiopathic hypertrophic subaortic stenosis. Am J Cardiol. 1963;11:8-17. [Medline] [Order article via Infotrieve]

22. Braunwald E, Brockenbrough E, Frye R. Studies on digitalis, V: comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophic subaortic stenosis. Circulation. 1962;26:166-173. [Abstract/Free Full Text]

23. Criley JM, Lewis KB, White RI Jr, Ross RS. Pressure gradients without obstruction: a new concept of `hypertrophic subaortic stenosis.' Circulation. 1965;22:881-887.

24. Ross J Jr, Braunwald E, Gault JH, Mason DT, Morrow AG. The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation. 1966;34:558-578. [Free Full Text]

25. Wigle ED, Marquis Y, Auger P. Muscular subaortic stenosis: initial left ventricular inflow tract pressure in the assessment of intraventricular pressure differences in man. Circulation. 1967;35:1100-1117. [Abstract/Free Full Text]

26. Wigle ED, Marquis Y, Auger P. Pharmacodynamics of mitral insufficiency in muscular subaortic stenosis. Can Med Assoc J. 1967;97:299-301. [Medline] [Order article via Infotrieve]

27. Wigle ED, Adelman AG, Auger P, Marquis Y. Mitral regurgitation in muscular subaortic stenosis. Am J Cardiol. 1969;24:698-706. [Medline] [Order article via Infotrieve]

28. Goodwin JF, Shah PM, Oakley CM, Cohen J, Yipintsoi T, Pocock W. Clinical pharmacology of hypertrophic obstructive cardiomyopathy. In: Wolstenholm GWE, O'Connor M, eds. Cardiomyopathies. Ciba Foundation Symposium. London, UK: Churchill; 1964:189-201.

29. Wigle ED, Adelman AG, Silver MD. Pathophysiological considerations in muscular subaortic stenosis. In: Wolstenholme GEW, O'Connor M, eds. Hypertrophic Obstructive Cardiomyopathy. Ciba Foundation Study Group 47. London, UK: Churchill; 1971:63-70.

30. Simon A, Ross J Jr, Gault JH. Angiographic anatomy of the left ventricle and mitral valve in idiopathic hypertrophic subaortic stenosis. Circulation. 1967;36:852-867. [Abstract/Free Full Text]

31. Dinsmore RE, Sanders CA, Harthorne JW. Mitral regurgitation in idiopathic hypertrophic subaortic stenosis. N Engl J Med. 1966;275:1225-1228.

32. Adelman AG, McLoughlin MJ, Marquis Y, Auger P, Wigle ED. Left ventricular cineangiographic observations in muscular subaortic stenosis. Am J Cardiol. 1969;24:689-697. [Medline] [Order article via Infotrieve]

33. Grose RM, Strain JE, Spindola-Franco H. Angiographic and hemodynamic correlations in hypertrophic cardiomyopathy. Am J Cardiol. 1986;58:1085-1092. [Medline] [Order article via Infotrieve]

34. Shah P, Gramiak R, Kramer D. Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation. 1969;40:3-11. [Abstract/Free Full Text]

35. Henry WL, Clark CE, Glancy DL, Epstein SE. Echocardiographic measurement of the left ventricular outflow gradient in idiopathic hypertrophic subaortic stenosis. N Engl J Med. 1973;288:989-993.

36. Henry WL, Clark CE, Griffith JM, Epstein SE. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis). Am J Cardiol. 1975;35:337-345. [Medline] [Order article via Infotrieve]

37. Popp RL, Harrison DC. Ultrasound in the diagnosis and evaluation of therapy of idiopathic hypertrophic subaortic stenosis. Circulation. 1969;40:905-914.

38. Martin RP, Rakowski H, French J, Popp RL. Idiopathic hypertrophic subaortic stenosis viewed by wide-angle, phased array echocardiography. Circulation. 1979;59:1206-1217. [Free Full Text]

39. Gilbert BW, Pollick C, Adelman AG, Wigle ED. Hypertrophic cardiomyopathy: subclassification by M-mode echocardiography. Am J Cardiol. 1980;45:861-872. [Medline] [Order article via Infotrieve]

40. Pollick C, Morgan CD, Gilbert BW, Rakowski H, Wigle ED. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and pressure gradient. Circulation. 1982;66:1087-1093. [Free Full Text]

41. Pollick C, Rakowski H, Wigle ED. Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. Circulation. 1984;69:43-49. [Abstract/Free Full Text]

42. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48:418-428. [Medline] [Order article via Infotrieve]

43. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315:610-614. [Abstract]

44. Appleton C, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol. 1988;12:426-440. [Abstract]

45. Shah PM, Taylor RD, Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in systolic anterior motion of mitral valve. Am J Cardiol. 1981;48:258-262. [Medline] [Order article via Infotrieve]

46. Yock PG, Hatle L, Popp RL. Patterns and timing of Doppler-detected intracavity and aortic flow in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:1047-1058. [Abstract]

47. Rakowski H, Sasson Z, Wigle ED. Echocardiographic and Doppler assessment of hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 1988;1:31-47. [Medline] [Order article via Infotrieve]

48. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992;20:42-52. [Abstract]

49. Bonow RO, Frederick RM, Bacharach SL, Green MV, Goose PW, Maron BJ, Rosing DR. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol. 1983;51:1386-1391. [Medline] [Order article via Infotrieve]

50. Bonow RD, Ostrow HG, Rosing DR, Cannon RO, Lipson LC, Maron BJ, Kent KM, Macharch SL, Green MV. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure volume analysis with a nonimaging scintillation probe. Circulation. 1983;68:1062-1073. [Abstract/Free Full Text]

51. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short and long term effects. Circulation. 1985;72:853-864. [Abstract/Free Full Text]

52. Cannon RO, Dilsizian V, O'Gara PT, Udelson JE, Tucker E, Panza JA, Fananapazir L, McIntosh CL, Wallace RB, Bonow RO. Impact of operative relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation. 1992;85:1039-1045. [Abstract/Free Full Text]

53. Takata J, Counihan PJ, Gane JN, Yoshinori D, Chikamori T, Ozawa T, McKenna WJ. Regional thallium-201 washout and myocardial hypertrophy in hypertrophic cardiomyopathy and its relation to exertional chest pain. Am J Cardiol. 1993;72:211-218. [Medline] [Order article via Infotrieve]

54. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22:796-804. [Abstract]

55. Higgins CB, Byrd BF, Stark D, McNamara M, Lanzer P, Lipton MJ, Schiller NB, Botvinick E, Chatterjee K. Magnetic resonance imaging in hypertrophic cardiomyopathy. Am J Cardiol. 1985;55:1121-1126. [Medline] [Order article via Infotrieve]

56. Suzuki J, Watanabe F, Takenaka K, Amano K, Amano W, Igarashi T, Aoki T, Serizawa T, Sakamoto T, Sugimoto T, Nishikawa JI. New subtype of apical hypertrophic cardiomyopathy identified with nuclear magnetic resonance imaging as an underlying cause of markedly inverted T-waves. J Am Coll Cardiol. 1993;22:1175-1181. [Abstract]

57. Webb JG, Sasson Z, Rakowski H, Liu P, Wigle ED. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J Am Coll Cardiol. 1990;15:83-90. [Abstract]

58. Gaudio C, Pelliccia F, Tanzilli G, Mazzarotto P, Cianfrocca C, Marino B. Magnetic resonance imaging for assessment of apical hypertrophy in hypertrophic cardiomyopathy. Clin Cardiol. 1992;15:164-168. [Medline] [Order article via Infotrieve]

59. Nienaber CA, Gambhir SS, Mody FV, Ratib O, Huang SC, Phelps ME, Schelbert HR. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation. 1993;87:1580-1590. [Abstract/Free Full Text]

60. Perrone-Filardi P, Bacharach SL, Dilsizian V, Panza JA, Maurea S, Bonow RO. Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy. Am J Cardiol. 1993;72:199-204. [Medline] [Order article via Infotrieve]

61. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy, I: influence on prognosis. Br Heart J. 1981;46:168-172. [Abstract/Free Full Text]

62. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol. 1981;48:252-257. [Medline] [Order article via Infotrieve]

63. Fananapazir L, Chang AC, Epstein SE, McAreavy D. Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation. 1992;86:730-740. [Abstract/Free Full Text]

64. Buja G, Miorelli M, Turrini P, Melacini P, Nava A. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol. 1993;72:973-976. [Medline] [Order article via Infotrieve]

65. Fauchier JP, Cosnay P, Moquet B, Balleh H, Rouesnel P. Late ventricular potentials and spontaneous and induced ventricular arrhythmias in dilated or hypertrophic cardiomyopathies: a prospective study about 83 patients. PACE Pacing Clin Electrophysiol. 1988;11:1974-1983. [Medline] [Order article via Infotrieve]

66. Jarcho JA, McKenna W, Pare PJA, Solomon SD, Geisterfer-Lowrance A, Holcombe RF, Dickie S, Levi T, Donsi-Keller H, Seidman JG, Seidman CE. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989;321:1372-1378. [Abstract]

67. Geisterfer-Lowrance A, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a ß-cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999-1006. [Medline] [Order article via Infotrieve]

68. Solomon SC, Jarcho JA, McKenna W, Geisterfer-Lowrance A, Germain R, Salerni R, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest. 1990;86:993-999.

69. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108-1114. [Abstract]

70. Hejtmancik JF, Brink PA, Towbin J, Hill R, Brink L, Tapscott T, Trakhtenbroit A, Roberts R. Localization of gene for hypertrophic cardiomyopathy to chromosome 14q1 in a diverse US population. Circulation. 1991;83:1592-1597. [Abstract/Free Full Text]

71. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in ß-myosin heavy chain gene. Circulation. 1992;86:345-352. [Abstract/Free Full Text]

72. Perryman MB, Yu QT, Marian AJ, Mares A, Czernuszewicz G, Ifegwu J, Hill R, Roberts R. Expression of missense mutation in the messenger RNA for ß-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy. J Clin Invest. 1992;90:271-277.

73. Carrier L, Hengstenberg C, Beckmann JS, Guicheny P, Dufour C, Bercovici J, Dausse E, Berebbi-Bertrand I, Wisnewsky C, Pulvenis D, Fetler L, Vignal A, Weissenbach J, Hillaire D, Feingold J, Bourhour JB, Hagege A, Desnos M, Isnard R, Dubourg O, Komajda M, Schwartz K. Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat Genet. 1993;4:311-314. [Medline] [Order article via Infotrieve]

74. Watkins H, MacRae C, Thierfelder L, Chou YH, Frenneaux MP, McKenna W, Seidman JG, Seidman CE. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet. 1993;3:333-337. [Medline] [Order article via Infotrieve]

75. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical ß-myosin heavy chain gene mutations. Circulation. 1994;89:22-32. [Abstract/Free Full Text]

76. Roberts R. Molecular genetics: therapy or terror? Circulation. 1994;89:499-502. Editorial. [Free Full Text]

77. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, Seidman CE. -Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77:701-712. [Medline] [Order article via Infotrieve]

78. Thierfelder L, MacRae C, Watkins H, McKenna W, Vosberg HP, Seidman JG, Seidman C. Familial hypertrophic cardiomyopathy is a disease of the sarcomere. Circulation. 1994;90(suppl I):I-519. Abstract.

79. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG, Seidman CE. Mutations in the genes for cardiac troponin T and -tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332:1058-1064. [Abstract/Free Full Text]

80. MacRae C, Ghaisas N, McGarry K, McKenna W, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. Circulation. 1994;90(suppl I):I-25. Abstract.

81. Takemura G, Fujiwara H, Mukoyama M, Saito Y, Nakao K, Kawamura A, Ishida M, Kida M, Uegaito T, Tanaka M, Matsumori A, Fujiwara T, Imura H, Kawai C. Expression and distribution of atrial natriuretic peptide in human hypertrophic ventricle of hypertensive hearts and hearts with hypertrophic cardiomyopathy. Circulation. 1991;83:181-190. [Abstract/Free Full Text]

82. Derchi G, Bellone P, Chiarella F, Randazzo M, Zino V, Vecchio C. Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:1502-1504. [Medline] [Order article via Infotrieve]

83. Dimitow PP, Surdaci A, Dubiel JS, Herman ZS. Plasma levels of atrial natriuretic peptide at rest, peak exercise and during recovery period in hypertrophic cardiomyopathy. Eur Heart J. 1994;15:198. Abstract.

84. Slade AKB, Grace AA, Prasad K, Marwaha GK, Seo H, Holt DW, Camm AJ, McKenna WJ. Plasma levels of brain natriuretic peptide are increased in hypertrophic cardiomyopathy. Eur Heart J. 1994;15:198. Abstract.

85. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1933;342:1085-1086.

86. Lechin M, Yu QT, Prather A, Hill R, Quinones M, Roberts R, Marian AJ. Angiotension converting enzyme genotype DD is associated with increased left ventricular mass in patients with hypertrophic cardiomyopathy. Circulation. 1994;90(suppl I):I-174. Abstract.

87. Maron BJ, Lipson LC, Roberts WG, Epstein SE. `Malignant' hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol. 1978;41:1133-1140. [Medline] [Order article via Infotrieve]

88. Falicov RE, Resnekov L, Bharati S, Lev M. Midventricular obstruction: a variant of obstructive cardiomyopathy. Am J Cardiol. 1976;37:432-437. [Medline] [Order article via Infotrieve]

89. Falicov RE, Resnekov L. Midventricular obstruction in hypertrophic obstructive cardiomyopathy: new diagnostic and therapeutic challenge. Br Heart J. 1977;39:701-705. [Free Full Text]

90. Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction. J Am Coll Cardiol. 1987;9:288-294. [Abstract]

91. Ishwata S, Nishyama S, Nakanishi S, Sekie A. Two types of left ventricular wall motion abnormalities with distinct clinical features in patients with hypertrophic cardiomyopathy. Eur Heart J. 1993;14:1629-1639. [Abstract/Free Full Text]

92. Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y, Hayashi T, Amano K. Giant negative T-wave inversion as a manifestation of asymmetric apical hypertrophy (AAH) of the left ventricle: echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J. 1976;17:611-629. [Medline] [Order article via Infotrieve]

93. Yamaguchi H, Ishimura T, Nishiyama S, Nagasaki F, Nakanishi S, Takatsu F, Nishijo T, Umeda T, Machii K. Hypertrophic nonobstructive cardiomyopathy with giant negative T-waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol. 1979;44:401-411.[Medline] [Order article via Infotrieve]

94. Keren G, Belhassen B, Sherez J, Miller HI, Megidish R, Berenfeld D, Laniado S. Apical hypertrophic cardiomyopathy: evaluation by noninvasive and invasive techniques in 23 patients. Circulation. 1985;71:45-56. [Abstract/Free Full Text]

95. Pai RG, Jintapakom W, Tanimoto M, Shah PM. Papillary muscle position and mitral apparatus structure in hypertrophic obstructive cardiomyopathy (HOCM) compared to cavity obliteration (CO). Circulation. 1994;90(suppl I):I-171. Abstract.

96. Hagege AA, Mirochnik N, Besse B, Desnos M, Castaldo F, Guerot C. Is measurement of mitral valve length clinically useful in patients with left ventricular hypertrophy? Circulation. 1994;90(suppl I):I-223. Abstract.

97. Klues GH, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85:1651-1660. [Abstract/Free Full Text]

98. Jaing L, Levine RA, King ME, Weyman AE. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J. 1987;113:633-644. [Medline] [Order article via Infotrieve]

99. Sherrid MV, Chu CK, Delia E, Mogtader A, Dwyer EM. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22:816-825. [Abstract]

100. Wigle ED, Auger P, Marquis Y. Muscular subaortic stenosis: the direct relation between the intraventricular pressure gradient and left ventricular ejection time. Circulation. 1967;36:36-44. [Abstract/Free Full Text]

101. Sasson Z, Henderson M, Wilansky S, Rakowski H, Wigle ED. Causal relation between the pressure gradient and left ventricular ejection time in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989;13:1275-1279. [Abstract]

102. Schwammenthal E, Nakatani S, Lever HM, Weyman AE, Levine RA. Intraoperative transesophageal studies of the mechanism of mitral regurgitation in hypertrophic cardiomyopathy. Circulation. 1994;90(suppl I):I-70. Abstract.

103. Jenni R, Ruffman K, Vieli A, Anlinker M, Krayenbuehl HP. Dynamics of aortic flow in hypertrophic cardiomyopathy. Eur Heart J. 1985;6:391-397. [Abstract/Free Full Text]

104. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction. Circulation. 1991;84:1188-1197. [Abstract/Free Full Text]

105. Petrone RK, Klues HG, Panza JA, Peterson EE, Maron BJ. Significance of the occurrence of mitral valve prolapse in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20:55-61. [Abstract]

106. Klues HG, Leuner C, Kuhn H. Hypertrophic obstructive cardiomyopathy: no increase in the gradient during exercise. J Am Coll Cardiol. 1991;19:527-533.

107. Decoulx E, Goullard L, Millaire A, Lecroart JL, de Groote P, Houdas Y, Ducloux G. Left intraventricular gradients measured by Doppler echocardiography at rest, during exercise and during isoproterenol test in hypertrophic cardiomyopathy. Arch Mal Coeur Vaiss. 1992;85:839-845. [Medline] [Order article via Infotrieve]

108. Schwammenthal E, Schwartzkopff B, Block M, Johns J, Losse B, Engberding R, Borggrefe M, Breithardt G. Doppler echocardiographic assessment of the pressure gradient during bicycle ergometry in hypertrophic cardiomyopathy. Am J Cardiol. 1992;69:1623-1628. [Medline] [Order article via Infotrieve]

109. Shima T, Nakamura T, Hirasaki S, Narihara R, Azuma A, Sugihara H, Kohno Y, Asayama J, Nakagawa M. Postprandial exacerbation of symptoms in patients with hypertrophic cardiomyopathy. Circulation. 1994;90(suppl I):I-385. Abstract.

110. Oakley CM. Hypertrophic obstructive cardiomyopathy: patterns of progression. In: Wolstenholm GEW, O'Connor M, eds. Hypertrophic Obstructive Cardiomyopathy. Ciba Foundation Study Group 37. London, UK: J&A Churchill; 1971:9-29.

111. ten Cate FJ, Roelandt J. Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy. Am Heart J. 1979;97:762-765. [Medline] [Order article via Infotrieve]

112. Waller BF, Maron BJ, Epstein SE, Roberts WC. Transmural myocardial infarction in hypertrophic cardiomyopathy: a cause of conversion from left ventricular asymmetry to symmetry and from normal sized to dilated left ventricular cavity. Chest. 1981;79:461-465. [Abstract/Free Full Text]

113. Ciro E, Marion BJ, Bonow RO, Cannon RO, Epstein SE. Relation between marked changes in left ventricular outflow tract gradient and disease progression in hypertrophic cardiomyopathy. Am J Cardiol. 1984;53:1103-1109. [Medline] [Order article via Infotrieve]

114. Tanaka M, Fujiwara H, Onodera T, Wu D-J, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts and hypertrophic cardiomyopathy. Br Heart J. 1986;55:575-581. [Abstract/Free Full Text]

115. Factor SM, Butany J, Sole MJ, Wigle ED, Williams WG, Rojkind M. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991;17:1343-1351. [Abstract]

116. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol. 1979;43:1086-1102. [Medline] [Order article via Infotrieve]

117. Brutsaert DL, Housmans PR, Goethais MA. Dual control of relaxation: its role in the ventricular function in the mammalian heart. Circ Res. 1980;47:637-652. [Free Full Text]

118. Brutsaert DL, Rademakers FE, Sys SU. Triple control of relaxation: implications in cardiac disease. Circulation. 1984;69:190-196. [Free Full Text]

119. Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications. J Am Coll Cardiol. 1993;22:318-325. [Abstract]

120. Wigle ED, Wilansky S. Diastolic dysfunction in hypertrophic cardiomyopathy. Heart Failure. 1987;3:82-93.

121. Gaasch WH, Levine HJ, Quinones MA, Alexander JK. Left ventricular compliance: mechanisms and clinical implications. Am J Cardiol. 1976;38:645-653. [Medline] [Order article via Infotrieve]

122. Morgan MP, Morgan KG. Intracellular calcium levels during contraction and relaxation of mammalian cardiac vascular smooth muscle as detected with aequorin. Am J Med. 1984;77:33-46.

123. Gwathmey JK, Warren SE, Briggs GM, Copelas L, Feldman MD, Phillips PJ, Callahan M, Schoen FJ, Grossman W, Morgan JP. Diastolic dysfunction in hypertrophic cardiomyopathy: effect on active force generation during systole. J Clin Invest. 1991;87:1023-1031.

124. Bonow RO, Vitale DF, Maron BJ, Bacharach SL, Frederick TM, Green MV. Regional left ventricular asynchrony and impaired global ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. J Am Coll Cardiol. 1987;9:1108-1116. [Abstract]

125. Pagani M, Pizzinelli P, Gussoni M, Craig WE, Pasipoularides A, Murgo JP. Diastolic abnormalities of hypertrophic cardiomyopathy reproduced by asynchrony of the left ventricle in conscious dogs. J Am Coll Cardiol. 1983;1:641. Abstract.

126. Inoue T, Morooka S, Hayashi T, Takayanagi K, Sakai Y, Fujito T, Fujinuma S, Takabatake Y. Global and regional abnormalities of left ventricular diastolic filling in hypertrophic cardiomyopathy. Clin Cardiol. 1991;14:573-577. [Medline] [Order article via Infotrieve]

127. Hanrath P, Mathey DG, Siegert R, Bleifeld W. Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: an echocardiographic study. Am J Cardiol. 1980;45:15-23. [Medline] [Order article via Infotrieve]

128. Maron BJ, Spirito P, Greene KJ, Wesley YE, Bonow RO, Arce J. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:733-742. [Abstract]

129. Cannon RO, Rosing DR, Maron BJ, Leon MB, Bonow RO, Watson RM, Epstein SE. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation. 1985;71:234-243. [Abstract/Free Full Text]

130. Cannon RO III, Schenke WH, Maron BJ, Tracy CM, Leon MB, Brush JE, Rosing DR, Epstein SE. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:53-62. [Abstract]

131. Cannon RO, Dilsizian V, O'Gara PT, Udelson JE, Schenke WH, Quyyumi A, Fananapazir L, Bonow RO. Myocardial metabolic, hemodynamic and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation. 1991;83:1660-1667. [Abstract/Free Full Text]

132. Brachfeld N, Gorlin R. Subaortic stenosis: a revised concept of the disease. Medicine (Baltimore). 1959;38:415-433. [Medline] [Order article via Infotrieve]

133. Wigle ED. Muscular subaortic stenosis: the clinical syndrome with additional evidence of ventricular septal hypertrophy. In: Wolstenholme GEW, O'Connor M, eds. Cardiomyopathies. Ciba Foundation Symposium. London, UK: Churchill; 1964:49-69.

134. McKenna WJ, Deanfield J, Faruqui A, England D, Oakley CM, Goodwin JF. Prognosis in hypertrophic cardiomyopathy: role of age, and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47:532-538. [Medline] [Order article via Infotrieve]

135. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile in 78 patients. Circulation. 1982;65:1388-1394. [Abstract/Free Full Text]

136. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child. 1984;59:971-975. [Abstract/Free Full Text]

137. McKenna W, Harris L, Deanfield J. Syncope in hypertrophic cardiomyopathy. Br Heart J. 1982;47:177-179. [Abstract/Free Full Text]

138. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation. 1989;80:1489-1492. [Free Full Text]

139. Schiavone WA, Maloney JD, Lever HM, Castle LW, Sterba R, Morant V. Electrophysiologic studies of patients with hypertrophic cardiomyopathy with syncope of undetermined etiology. PACE Pacing Clin Electrophysiol. 1986;9:476-481. [Medline] [Order article via Infotrieve]

140. Spirito P, Rapezzi C, Autore C, Bruzzi P, Ortolani P, Fragola P, Chiarella F, Berisso M, Cannata D, Branzi A, Vecchio C. Prognostic significance of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: an accepted dogma revisited. Circulation. 1993;88(suppl I):I-210. Abstract.

141. McAreavey D, Fananapazir L. DDD pacing may obviate the need for investigation of symptoms of impaired consciousness in hypertrophic cardiomyopathy. Circulation. 1994;90(suppl I):I-443. Abstract.

142. Borggrefe M, Schwammenthal E, Block M, Schulte HD. Pre and postoperative electrophysiologic findings in survivors of cardiac arrest and hypertrophic obstructive cardiomyopathy undergoing myectomy. Circulation. 1993;88(suppl I):I-210. Abstract.

143. McAreavey D, Dilsizian V, Panza J, Fananapazir L. Favorable prognosis in 88 young hypertrophic cardiomyopathy patients during therapy based on hemodynamic electrophysiologic and thallium scintigraphy findings. Circulation. 1993;88(suppl I):I-209. Abstract.

144. Frenneaux MP, Counihan PJ, Caforio ALP, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation. 1990;82:1995-2002. [Abstract/Free Full Text]

145. Gilligan DM, Nihoyannopoulos P, Chan WL, Oakley CM. Investigation of a hemodynamic basis for syncope in hypertrophic cardiomyopathy: use of a head-up tilt test. Circulation. 1992;85:2140-2148. [Abstract/Free Full Text]

146. Adelman AG, Wigle ED, Ranganathan N, Webb GD, Kidd BSL, Bigelow WG, Silver MD. The clinical course in muscular subaortic stenosis: a retrospective and prospective study of 60 hemodynamically proved cases. Ann Intern Med. 1972;77:515-525.

147. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320:749-755. [Abstract]

148. Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol. 1993;72:939-943. [Medline] [Order article via Infotrieve]

149. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. 1986;7:204-214. [Abstract]

150. Wigle ED, Baron R. The electrocardiogram in muscular subaortic stenosis: the effect of a left septal incision and right bundle branch block. Circulation. 1965;34:585-591. [Abstract/Free Full Text]

151. McKenna WJ, Stewart JT, Nihoyannopoulos P, McGinty F, Davies MJ. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J. 1990;63:287-290. [Abstract/Free Full Text]

152. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol. 1983;2:437-444. [Abstract]

153. Marwick TH, Stewart WJ, Lever HM, Lytle BW, Rosenkranz ER, Duffy CI, Ernesto D, Salcedo E. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20:1066-1072. [Abstract]

154. Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross J Jr. Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation. 1964;29:84-98. [Abstract/Free Full Text]

155. Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847-851. [Abstract/Free Full Text]

156. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis: prevention of outflow obstruction with propranolol. Circulation. 1968;38:846-858. [Abstract/Free Full Text]

157. Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J. 1970;32:804-811. [Abstract/Free Full Text]

158. Stenson RE, Flamm MD Jr, Harrison DC, Hancock EW. Hypertrophic subaortic stenosis: clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol. 1973;31:763-773. [Medline] [Order article via Infotrieve]

159. Wigle ED, Adelman AG, Felderhof CH. Medical and surgi-cal treatment of cardiomyopathies. Circ Res. 1974;35(suppl II):II-196-II-207.

160. Frank MJ, Abdulla AM, Canedo MI, Saylors RE. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol. 1978;42:993-1001. [Medline] [Order article via Infotrieve]

161. Swanton RH, Brooksby IAB, Jenkins BS, Webb-Peploe MM. Hemodynamic studies of B blockade in hypertrophic obstructive cardiomyopathy. Eur J Cardiol. 1977;5:327-341. [Medline] [Order article via Infotrieve]

162. Speiser KW, Krayenbuehl HP. Reappraisal of effect of acute beta blockade on left ventricular filling dynamics in hypertrophic obstructive cardiomyopathy. Eur Heart J. 1981;2:21-29. [Abstract/Free Full Text]

163. Kaltenbach M, Hopf R, Kober G, Bussman WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979;42:35-42. [Abstract/Free Full Text]

164. Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE. Verapamil therapy: new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, I: hemodynamic effects. Circulation. 1979;60:1201-1207. [Abstract/Free Full Text]

165. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, II: effects on exercise capacity and symptomatic status. Circulation. 1979;60:1208-1213. [Free Full Text]

166. Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, Lipson LC, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, III: effects of long-term administration. Am J Cardiol. 1981;48:545-553. [Medline] [Order article via Infotrieve]

167. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complication in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:437-441. [Abstract/Free Full Text]

168. Lorell BH, Paulus WJ, Grossman W, Wynne J, Cohn PF. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy. Circulation. 1982;65:499-507. [Abstract/Free Full Text]

169. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307:997-999. [Medline] [Order article via Infotrieve]

170. Pollick C, Kimball BP, Hendreson M, Wigle ED. Disopyramide in hypertrophic cardiomyopathy: hemodynamic assessment after intravenous administration. Am J Cardiol. 1988;62:1248-1251. [Medline] [Order article via Infotrieve]

171. Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1988;62:1085-1088. [Medline] [Order article via Infotrieve]

172. Kimball BP, Bui S, Wigle ED. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am Heart J. 1993;125:1691-1697. [Medline] [Order article via Infotrieve]

173. Hassenstein P, Storch HH, Schmitz W. Erfahrungen mit der Schrittmacherdauerbehandlung bei Patienten mit obstrucktiver Kardiomyopathie. Thoraxchirurgie. 1975;23:496-499.

174. Johnson AD, Daily PO. Hypertrophic subaortic stenosis complicated by high degree heart block: successful treatment with atrial synchronous ventricular pacemaker. Chest. 1975;67:491-494. [Abstract/Free Full Text]

175. Duck HJ, Hutschemeiter W, Paneau H, Trenchmann H. Atrioventricular stimulation with reduced AV delay time as a therapeutic principle in hypertrophic obstructive cardiomyopathy. Z Gesamte Inn Med. 1984;39:437-447. [Medline] [Order article via Infotrieve]

176. McDonald K, McWilliams E, O'Keeffe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J. 1988;9:893-898. [Abstract/Free Full Text]

177. Fananapazir L, Cannon RO, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and B-adrenergic blocker therapy. Circulation. 1992;85:2149-2161. [Abstract/Free Full Text]

178. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet. 1992;339:1318-1323. [Medline] [Order article via Infotrieve]

179. Nishimura RA, Danielson GK. Dual chamber pacing for hypertrophic obstructive cardiomyopathy: has its time come? Br Heart J. 1993;70:301-303. [Free Full Text]

180. Prinzen FW, van Oosterhout MFM, Delhaas T, Arts T, Reneman RS. Epicardial ventricular pacing at physiological heart rate leads to asymmetrical changes in left ventricular wall thickness. Eur Heart J. 1994;15(suppl):76. Abstract.

181. Betocchi S, Losi MA, Piscione F, Perrone-Filardi P, Pace L, Boccalatte M, Salvatore M, Chiariello M. Effects of atrioventricular pacing on obstruction and on diastolic function in hypertrophic cardiomyopathy. Eur Heart J. 1994;15(suppl):521. Abstract.

182. Nishimura RA, Hayes DL, Holmes DR, Tajik AJ. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol. In press.

183. Gras D, De Place C, Leclercq C, Le Breton H, Mabo P, Daubert C. Key importance to individually optimize atrioventricular synchrony in obstructive hypertrophic cardiomyopathy treated by DDD-pacing. Eur Heart J. 1994;15(suppl):522. Abstract.

184. Barold S, Kappenberger L, Daubert C, Fontaine G. Dual chamber pacemaker therapy in cardiomyopathy. In: Aubert AE, Ector H, Stroobandt R, eds. Cardiac Pacing and Electrophysiology. Dordrecht, Netherlands: Kluwer Academic Publishers; 1994:269-279.

185. Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg. 1961;154:181-189. [Medline] [Order article via Infotrieve]

186. Cleland WP. The surgical management of obstructive cardiomyopathy. J Cardiovasc Surg. 1963;4:489-491.

187. Kirklin JW, Ellis FR Jr. Surgical relief of diffuse subvalvular aortic stenosis. Circulation. 1961;24:739-742. [Abstract/Free Full Text]

188. Wigle ED, Chrysohou A, Bigelow W. Results of ventriculomyotomy in muscular subaortic stenosis. Am J Cardiol. 1963;11:572-586. [Medline] [Order article via Infotrieve]

189. Bigelow WG, Trimble AS, Wigle ED, Adelman AG, Felderhof CH. The treatment of muscular subaortic stenosis. J Thorac Cardiovasc Surg. 1974;68:384-392. [Medline] [Order article via Infotrieve]

190. Agnew TM, Barratt-Boyes BG, Brandt PWT, Roche AHG, Lowe JB, O'Brien KP. Surgical resection in idiopathic hypertrophic subaortic stenosis with a combined approach through aorta and left ventricle. J Thorac Cardiovasc Surg. 1977;74:307-316. [Abstract]

191. Maron BJ, Epstein SE, Morrow AG. Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur Heart J. 1983;4(suppl F):175-185.

192. Beahrs MM, Tajik AJ, Seward JB, Giuliani ER, McGoon DC. Hypertrophic obstructive cardiomyopathy: 10-21 year follow-up after partial septal myectomy. Am J Cardiol. 1983;51:1160-1166. [Medline] [Order article via Infotrieve]

193. Mohr R, Schaff HV, Danielson GK, Puga FJ, Pluth JR, Tajik AJ. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy: experience over 15 years. J Thorac Cardiovasc Surg. 1989;97:666-674. [Abstract]

194. Bircks W, Schulte HD. Surgical treatment of hypertrophic obstructive cardiomyopathy with special reference to complications and to atypical hypertrophic obstructive cardiomyopathy. Eur Heart J. 1983;4(suppl F):187-190.

195. McIntosh CL, Maron BJ. Current operative treatment of obstruc-tive hypertrophic cardiomyopathy. Circulation. 1988;78:487-495. [Free Full Text]

196. Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for idiopathic hypertrophic obstructive cardiomyopathy. Circulation. 1987;76(suppl V):V-104-V-108.

197. Cohn LH, Trehan H, Collins JJ. Long-term follow-up of patients undergoing myotomy-myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:657-660. [Medline] [Order article via Infotrieve]

198. Turina J, Jenni R, Krayenbuehl HP, Turina M, Rothlin M. Echocardiographic findings late after myectomy in hypertrophic obstructive cardiomyopathy. Eur Heart J. 1986;7:685-692. [Abstract/Free Full Text]

199. ten Berg JM, Suttorp MJ, Knaepen PJ, Ernst SMPG, Vermeulen FEE, Jaarsma W. Hypertrophic obstructive cardiomyopathy: initial results and long-term follow-up after Morrow septal myectomy. Circulation. 1994;90:1781-1785. [Abstract/Free Full Text]

200. Weerasena N, Williams WG, Wigle ED, Rakowski H, Freedom RM. Septal myectomy for relief of obstructive hypertrophic cardiomyopathy. Circulation. 1994;90(suppl I):I-586. Abstract.

201. Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy: 10-year follow-up in 185 patients. Circulation. 1989;80(suppl II):II-57-II-64.

202. Glancy DL, O'Brien KP, Gold HK, Epstein SE. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J. 1970;32:652-659. [Abstract/Free Full Text]

203. Watson DC, Henry WL, Epstein SE, Morrow AG. Effects of operation on left atrial size and the occurrence of atrial fibrillation in patients with hypertrophic subaortic stenosis. Circulation. 1977;55:178-181. [Abstract/Free Full Text]

204. McKenna WJ, Harris L, Rowland E, Kleinebenne A, Krikler DM, Oakley CM, Goodwin JF. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol. 1984;54:802-810. [Medline] [Order article via Infotrieve]

205. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312:277-283. [Abstract]

206. Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly: distinctions from the young based on cardiac shape. Circulation. 1989;79:580-589. [Abstract/Free Full Text]

207. Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. J Am Coll Cardiol. 1989;13:36-45. [Abstract]

208. Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol. 1990;16:821-826. [Abstract]

209. Chikamori T, Doi YL, Yonezawa Y, Dickie S, Ozawa T, McKenna WJ. Comparison of clinical features in patients >60 years of age and those <40 years of age with hypertrophic cardiomyopathy. Am J Cardiol. 1990;66:875-877. [Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				L.K. Williams, M.P. Frenneaux, and R.P. Steeds Echocardiography in hypertrophic cardiomyopathy diagnosis, prognosis, and role in management Eur J Echocardiogr, December 1, 2009; 10(8): iii9 - iii14. [Abstract] [Full Text] [PDF]

				B R Anderson and V L Vetter Return to play? Practical considerations for young athletes with cardiovascular disease Br. J. Sports Med., September 1, 2009; 43(9): 690 - 695. [Abstract] [Full Text] [PDF]

				M. S. Maron, I. Olivotto, B. J. Maron, S. K. Prasad, F. Cecchi, J. E. Udelson, and P. G. Camici The case for myocardial ischemia in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., August 25, 2009; 54(9): 866 - 875. [Abstract] [Full Text] [PDF]

				K. Unno, S. Isobe, H. Izawa, X. W. Cheng, M. Kobayashi, A. Hirashiki, T. Yamada, K. Harada, S. Ohshima, A. Noda, et al. Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy Eur. Heart J., August 1, 2009; 30(15): 1853 - 1862. [Abstract] [Full Text] [PDF]

				B. J. Maron, M. S. Maron, E. D. Wigle, and E. Braunwald The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., July 14, 2009; 54(3): 191 - 200. [Abstract] [Full Text] [PDF]

				M. S. Maron, B. J. Maron, C. Harrigan, J. Buros, C. M. Gibson, I. Olivotto, L. Biller, J. R. Lesser, J. E. Udelson, W. J. Manning, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J. Am. Coll. Cardiol., July 14, 2009; 54(3): 220 - 228. [Abstract] [Full Text] [PDF]

				C. J. McLeod, M. J. Ackerman, R. A. Nishimura, A. J. Tajik, B. J. Gersh, and S. R. Ommen Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J. Am. Coll. Cardiol., July 14, 2009; 54(3): 229 - 233. [Abstract] [Full Text] [PDF]

				I A Paraskevaidis, F Panou, C Papadopoulos, D Farmakis, J Parissis, I Ikonomidis, A Rigopoulos, E K Iliodromitis, and D Th Kremastinos Evaluation of left atrial longitudinal function in patients with hypertrophic cardiomyopathy: a tissue Doppler imaging and two-dimensional strain study Heart, March 15, 2009; 95(6): 483 - 489. [Abstract] [Full Text] [PDF]

				B B Siswanto and R Aryani Recent advances in diagnosis and management of hypertrophic cardiomyopathy Heart Asia, March 1, 2009; 2009(3): 1 - 4. [Abstract] [Full Text] [PDF]

				O. M. Hess, W. McKenna, and H.-P. Schultheiss CHAPTER 18 Myocardial Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				L. C. Afonso, J. Bernal, J. J. Bax, and T. P. Abraham Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. J. Am. Coll. Cardiol. Img., November 1, 2008; 1(6): 787 - 800. [Abstract] [Full Text] [PDF]

				J. Ganame, R. H. Pignatelli, B. W. Eidem, P. Claus, J. D'hooge, C. J. McMahon, G. Buyse, J. A. Towbin, N. A. Ayres, and L. Mertens Myocardial deformation abnormalities in paediatric hypertrophic cardiomyopathy: are all aetiologies identical? Eur J Echocardiogr, November 1, 2008; 9(6): 784 - 790. [Abstract] [Full Text] [PDF]

				M. S. Maron, J. J. Finley, J. M. Bos, T. H. Hauser, W. J. Manning, T. S. Haas, J. R. Lesser, J. E. Udelson, M. J. Ackerman, and B. J. Maron Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy Circulation, October 7, 2008; 118(15): 1541 - 1549. [Abstract] [Full Text] [PDF]

				V. L. Fernandes, C. Nielsen, S. F. Nagueh, A. E. Herrin, C. Slifka, J. Franklin, and W. H. Spencer III Follow-Up of Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy: The Baylor and Medical University of South Carolina Experience 1996 to 2007 J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 561 - 570. [Abstract] [Full Text] [PDF]

				T S Kato, H Izawa, K Komamura, A Noda, H Asano, K Nagata, S Hashimoto, N Oda, C Kamiya, H Kanzaki, et al. Heterogeneity of regional systolic function detected by tissue Doppler imaging is linked to impaired global left ventricular relaxation in hypertrophic cardiomyopathy Heart, October 1, 2008; 94(10): 1302 - 1306. [Abstract] [Full Text] [PDF]

				M. S. Maron, E. Appelbaum, C. J. Harrigan, J. Buros, C. M. Gibson, C. Hanna, J. R. Lesser, J. E. Udelson, W. J. Manning, and B. J. Maron Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy Circ Heart Fail, September 1, 2008; 1(3): 184 - 191. [Abstract] [Full Text] [PDF]

				H. Rakowski and S. Carasso Quantifying Diastolic Function in Hypertrophic Cardiomyopathy: The Ongoing Search for the Holy Grail Circulation, December 4, 2007; 116(23): 2662 - 2665. [Full Text] [PDF]

				A. W. ElBardissi, J. A. Dearani, R. A. Nishimura, S. R. Ommen, J. M. Stulak, and H. V. Schaff Septal Myectomy After Previous Septal Artery Ablation in Hypertrophic Cardiomyopathy Mayo Clin. Proc., December 1, 2007; 82(12): 1516 - 1522. [Abstract] [Full Text] [PDF]

				J. Ker Solitary Papillary Muscle Hypertrophy: A New Echo-Electrocardiographic Syndrome? A Case Report Angiology, September 1, 2007; 58(4): 502 - 503. [Abstract] [PDF]

				A. Nasermoaddeli, K. Miura, A. Matsumori, Y. Soyama, Y. Morikawa, A. Kitabatake, Y. Inaba, and H. Nakagawa Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study Heart, June 1, 2007; 93(6): 711 - 715. [Abstract] [Full Text] [PDF]

				I. Barac, S. Upadya, R. Pilchik, G. Winson, M. Passick, F. A. Chaudhry, and M. V. Sherrid Effect of Obstruction on Longitudinal Left Ventricular Shortening in Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1203 - 1211. [Abstract] [Full Text] [PDF]

				Wenxia Chai, Y. M Hoedemaekers, R. H. van Schaik, M. van Fessem, I. M Garrelds, J. J Saris, D. Dooijes, F. J ten Cate, M. M. Kofflard, and A. J. Danser Cardiac aldosterone in subjects with hypertrophic cardiomyopathy Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 225 - 230. [Abstract] [PDF]

				R. A. Nishimura and S. R. Ommen Hypertrophic Cardiomyopathy: The Search for Obstruction Circulation, November 21, 2006; 114(21): 2200 - 2202. [Full Text] [PDF]

				M. S. Maron, I. Olivotto, A. G. Zenovich, M. S. Link, N. G. Pandian, J. T. Kuvin, S. Nistri, F. Cecchi, J. E. Udelson, and B. J. Maron Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction Circulation, November 21, 2006; 114(21): 2232 - 2239. [Abstract] [Full Text] [PDF]

				Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1064 - 1108. [Full Text] [PDF]

				Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]

				D. P. Zipes, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur. Heart J., September 1, 2006; 27(17): 2099 - 2140. [Full Text] [PDF]

				Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]

				Y. Notomi, M. G. Martin-Miklovic, S. J. Oryszak, T. Shiota, D. Deserranno, Z. B. Popovic, M. J. Garcia, N. L. Greenberg, and J. D. Thomas Enhanced Ventricular Untwisting During Exercise: A Mechanistic Manifestation of Elastic Recoil Described by Doppler Tissue Imaging Circulation, May 30, 2006; 113(21): 2524 - 2533. [Abstract] [Full Text] [PDF]

				D. M. Yoerger, C. A. Best, B. M. McQuillan, G. E. Supple, J. L. Guererro, J. E. Cluette-Brown, A. Hasaba, M. H. Picard, J. R. Stone, and M. Laposata Rapid Fatty Acid Ethyl Ester Synthesis by Porcine Myocardium Upon Ethanol Infusion into the Left Anterior Descending Coronary Artery Am. J. Pathol., May 1, 2006; 168(5): 1435 - 1442. [Abstract] [Full Text] [PDF]

				J. Binder, S. R. Ommen, B. J. Gersh, S. L. Van Driest, A. J. Tajik, R. A. Nishimura, and M. J. Ackerman Echocardiography-Guided Genetic Testing in Hypertrophic Cardiomyopathy: Septal Morphological Features Predict the Presence of Myofilament Mutations Mayo Clin. Proc., April 1, 2006; 81(4): 459 - 467. [Abstract] [Full Text] [PDF]

				K. Serri, P. Reant, M. Lafitte, M. Berhouet, V. Le Bouffos, R. Roudaut, and S. Lafitte Global and Regional Myocardial Function Quantification by Two-Dimensional Strain: Application in Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1175 - 1181. [Abstract] [Full Text] [PDF]

				S. Kido, N. Hasebe, Y. Ishii, and K. Kikuchi Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1064 - H1070. [Abstract] [Full Text] [PDF]

				S. R. Ommen, B. J. Maron, I. Olivotto, M. S. Maron, F. Cecchi, S. Betocchi, B. J. Gersh, M. J. Ackerman, R. B. McCully, J. A. Dearani, et al. Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., August 2, 2005; 46(3): 470 - 476. [Abstract] [Full Text] [PDF]

				I. Olivotto, M. S. Maron, A. S. Adabag, S. A. Casey, D. Vargiu, M. S. Link, J. E. Udelson, F. Cecchi, and B. J. Maron Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., August 2, 2005; 46(3): 480 - 487. [Abstract] [Full Text] [PDF]

				Y. Amano, S. Kumita, M. Takayama, and T. Kumazaki Comparison of Contrast-Enhanced MRI with Iodine-123 BMIPP for Detection of Myocardial Damage in Hypertrophic Cardiomyopathy Am. J. Roentgenol., August 1, 2005; 185(2): 312 - 318. [Abstract] [Full Text] [PDF]

				A. Woo, W. G. Williams, R. Choi, E. D. Wigle, E. Rozenblyum, K. Fedwick, S. Siu, A. Ralph-Edwards, and H. Rakowski Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy Circulation, April 26, 2005; 111(16): 2033 - 2041. [Abstract] [Full Text] [PDF]

				M. V. Sherrid, I. Barac, W. J. McKenna, P. M. Elliott, S. Dickie, L. Chojnowska, S. Casey, and B. J. Maron Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1251 - 1258. [Abstract] [Full Text] [PDF]

				B. J. Maron, M. J. Ackerman, R. A. Nishimura, R. E. Pyeritz, J. A. Towbin, and J. E. Udelson Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1340 - 1345. [Full Text] [PDF]

				M. Wall, C. A. Calvert, S. L. Sanderson, A. Leonhardt, C. Barker, and T. K. Fallaw Evaluation of Extended-Release Diltiazem Once Daily for Cats With Hypertrophic Cardiomyopathy J. Am. Anim. Hosp. Assoc., March 1, 2005; 41(2): 98 - 103. [Abstract] [Full Text] [PDF]

				A. S. Adabag, S. A. Casey, M. A. Kuskowski, A. G. Zenovich, and B. J. Maron Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy J. Am. Coll. Cardiol., March 1, 2005; 45(5): 697 - 704. [Abstract] [Full Text] [PDF]

				P. A. Kaufmann and P. G. Camici Myocardial Blood Flow Measurement by PET: Technical Aspects and Clinical Applications J. Nucl. Med., January 1, 2005; 46(1): 75 - 88. [Full Text] [PDF]

				T. S. Kato, A. Noda, H. Izawa, A. Yamada, K. Obata, K. Nagata, M. Iwase, T. Murohara, and M. Yokota Discrimination of Nonobstructive Hypertrophic Cardiomyopathy From Hypertensive Left Ventricular Hypertrophy on the Basis of Strain Rate Imaging by Tissue Doppler Ultrasonography Circulation, December 21, 2004; 110(25): 3808 - 3814. [Abstract] [Full Text] [PDF]

				B. J. Maron, J. A. Dearani, S. R. Ommen, M. S. Maron, H. V. Schaff, B. J. Gersh, and R. A. Nishimura The case for surgery in obstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2044 - 2053. [Abstract] [Full Text] [PDF]

				O. M. Hess and U. Sigwart New treatment strategies for hypertrophic obstructive cardiomyopathy: Alcohol ablation of the septum: the new gold standard? J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2054 - 2055. [Abstract] [Full Text] [PDF]

				L. Faber, H. Seggewiss, D. Welge, D. Fassbender, H. K. Schmidt, U. Gleichmann, and D. Horstkotte Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience Eur J Echocardiogr, October 1, 2004; 5(5): 347 - 355. [Abstract] [Full Text] [PDF]

				P Charron, E Villard, P Sebillon, P Laforet, T Maisonobe, L Duboscq-Bidot, N Romero, V Drouin-Garraud, T Frebourg, P Richard, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey Heart, August 1, 2004; 90(8): 842 - 846. [Abstract] [Full Text] [PDF]

				F H Gietzen, C J Leuner, L Obergassel, C Strunk-Mueller, and H Kuhn Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients Heart, June 1, 2004; 90(6): 638 - 644. [Abstract] [Full Text] [PDF]

				S A Mohiddin, Z M Ahmed, A J Griffith, D Tripodi, T B Friedman, L Fananapazir, and R J Morell Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6) J. Med. Genet., April 1, 2004; 41(4): 309 - 314. [Full Text] [PDF]

				B. J. Maron, V. N. Tholakanahalli, A. G. Zenovich, S. A. Casey, D. Duprez, D. M. Aeppli, and J. N. Cohn Usefulness of B-Type Natriuretic Peptide Assay in the Assessment of Symptomatic State in Hypertrophic Cardiomyopathy Circulation, March 2, 2004; 109(8): 984 - 989. [Abstract] [Full Text] [PDF]

				K. Minakata, J. A. Dearani, R. A. Nishimura, B. J. Maron, and G. K. Danielson Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 481 - 489. [Abstract] [Full Text] [PDF]

				W. G. van Dockum, F. J. ten Cate, J. M. ten Berg, A. M. Beek, J. W. R. Twisk, J. Vos, M. B. M. Hofman, C. A. Visser, and A. C. van Rossum Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging J. Am. Coll. Cardiol., January 7, 2004; 43(1): 27 - 34. [Abstract] [Full Text] [PDF]

				A. Rovner, R. Smith, N. L. Greenberg, E. M. Tuzcu, N. Smedira, H. M. Lever, J. D. Thomas, and M. J. Garcia Improvement in diastolic intraventricular pressure gradients in patients with HOCM after ethanol septal reduction Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2492 - H2499. [Abstract] [Full Text] [PDF]

				B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713. [Full Text] [PDF]

				Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991. [Full Text] [PDF]

				M. Hamada, Y. Shigematsu, K. Ohshima, J. Suzuki, A. Ogimoto, T. Ohtsuka, and Y. Hara Diagnostic Usefulness of Carotid Pulse Tracing in Patients With Hypertrophic Obstructive Cardiomyopathy Due to Midventricular Obstruction: A Comparison With Idiopathic Hypertrophic Subaortic Stenosis Chest, October 1, 2003; 124(4): 1275 - 1283. [Abstract] [Full Text] [PDF]

				B. J. Maron, S. A. Casey, R. G. Hauser, and D. M. Aeppli Clinical course of hypertrophiccardiomyopathy with survival to advanced age J. Am. Coll. Cardiol., September 3, 2003; 42(5): 882 - 888. [Abstract] [Full Text] [PDF]

				B J Maron Contemporary considerations for risk stratification, sudden death and prevention in hypertrophic cardiomyopathy Heart, September 1, 2003; 89(9): 977 - 978. [Full Text] [PDF]

				E. D Grech Non-coronary percutaneous intervention BMJ, July 10, 2003; 327(7406): 97 - 100. [Full Text] [PDF]

				H. Izawa, M. Iwase, Y. Takeichi, F. Somura, K. Nagata, T. Nishizawa, A. Noda, T. Murohara, and M. Yokota Effect of Nicorandil on Left Ventricular End-Diastolic Pressure During Exercise in Patients with Hypertrophic Cardiomyopathy Eur. Heart J., July 2, 2003; 24(14): 1340 - 1348. [Abstract] [Full Text] [PDF]

				B. J. Maron, N. A. M. Estes III, M. S. Maron, A. K. Almquist, M. S. Link, and J. E. Udelson Primary Prevention of Sudden Death as a Novel Treatment Strategy in Hypertrophic Cardiomyopathy Circulation, June 17, 2003; 107(23): 2872 - 2875. [Full Text] [PDF]

				P. Sipola, E. Vanninen, H. J. Aronen, K. Lauerma, S. Simula, P. Jaaskelainen, M. Laakso, K. Peuhkurinen, J. Kuusisto, and J. T. Kuikka Cardiac Adrenergic Activity Is Associated with Left Ventricular Hypertrophy in Genetically Homogeneous Subjects with Hypertrophic Cardiomyopathy J. Nucl. Med., April 1, 2003; 44(4): 487 - 493. [Abstract] [Full Text] [PDF]

				T. Konno, M. Shimizu, H. Ino, T. Matsuyama, M. Yamaguchi, H. Terai, K. Hayashi, T. Mabuchi, M. Kiyama, K. Sakata, et al. A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients J. Am. Coll. Cardiol., March 5, 2003; 41(5): 781 - 786. [Abstract] [Full Text] [PDF]

				M. V. Sherrid, F. A. Chaudhry, and D. G. Swistel Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction Ann. Thorac. Surg., February 1, 2003; 75(2): 620 - 632. [Abstract] [Full Text] [PDF]

				M. S. Maron, I. Olivotto, S. Betocchi, S. A. Casey, J. R. Lesser, M. A. Losi, F. Cecchi, and B. J. Maron Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy N. Engl. J. Med., January 23, 2003; 348(4): 295 - 303. [Abstract] [Full Text] [PDF]

				C. Seidman Genetic Causes of Inherited Cardiac Hypertrophy: Robert L. Frye Lecture Mayo Clin. Proc., December 1, 2002; 77(12): 1315 - 1319. [Abstract] [PDF]

				C. Autore, M. R. Conte, M. Piccininno, P. Bernabo, G. Bonfiglio, P. Bruzzi, and P. Spirito Risk associated with pregnancy in hypertrophic cardiomyopathy J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1864 - 1869. [Abstract] [Full Text] [PDF]

				P Charron, D Heron, M Gargiulo, P Richard, O Dubourg, M Desnos, J-B Bouhour, J Feingold, L Carrier, B Hainque, et al. Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience J. Med. Genet., October 1, 2002; 39(10): 741 - 746. [Abstract] [Full Text] [PDF]

				E. Braunwald, C. E. Seidman, and U. Sigwart Contemporary Evaluation and Management of Hypertrophic Cardiomyopathy Circulation, September 10, 2002; 106(11): 1312 - 1316. [Full Text] [PDF]

				F. H. Gietzen, C. J. Leuner, L. Obergassel, C. Strunk-Mueller, and H. Kuhn Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions Circulation, July 23, 2002; 106(4): 454 - 459. [Abstract] [Full Text] [PDF]

				Q. Ciampi, S. Betocchi, R. Lombardi, F. Manganelli, G. Storto, M. A. Losi, E. Pezzella, F. Finizio, A. Cuocolo, and M. Chiariello Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy J. Am. Coll. Cardiol., July 17, 2002; 40(2): 278 - 284. [Abstract] [Full Text] [PDF]

				J.-J. Hwang, P. D. Allen, G. C. Tseng, C.-W. Lam, L. Fananapazir, V. J. Dzau, and C.-C. Liew Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure Physiol Genomics, July 12, 2002; 10(1): 31 - 44. [Abstract] [Full Text] [PDF]

				B. J. Maron Hypertrophic Cardiomyopathy: A Systematic Review JAMA, March 13, 2002; 287(10): 1308 - 1320. [Abstract] [Full Text] [PDF]

				B. J. Maron, I. Olivotto, P. Bellone, M. R. Conte, F. Cecchi, B. P. Flygenring, S. A. Casey, T. E. Gohman, S. Bongioanni, and P. Spirito Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., January 16, 2002; 39(2): 301 - 307. [Abstract] [Full Text] [PDF]

				A. MAASS, J.P. KONHILAS, B.L. STAUFFER, and L.A. LEINWAND From Sarcomeric Mutations to Heart Disease: Understanding Familial Hypertrophic Cardiomyopathy Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 409 - 416. [Abstract] [PDF]

				J. Xin, T. Shiota, H. M. Lever, S. R. Kapadia, M. Sitges, D. N. Rubin, F. Bauer, N. L. Greenberg, D. A. Agler, J. K. Drinko, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1994 - 2000. [Abstract] [Full Text] [PDF]

				E D. Wigle CARDIOMYOPATHY: The diagnosis of hypertrophic cardiomyopathy Heart, December 1, 2001; 86(6): 709 - 714. [Full Text] [PDF]

				P. S. Andersen, O. Havndrup, H. Bundgaard, J. C. Moolman-Smook, L. A. Larsen, J. Mogensen, P. A. Brink, A. D. Borglum, V. A. Corfield, K. Kjeldsen, et al. Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and South African populations J. Med. Genet., December 1, 2001; 38 (12): e43 - e43. [Full Text] [PDF]

				J. Deinum, J. M.G. van Gool, M. J.M. Kofflard, F. J. ten Cate, and A.H. J. Danser Angiotensin II Type 2 Receptors and Cardiac Hypertrophy in Women With Hypertrophic Cardiomyopathy Hypertension, December 1, 2001; 38(6): 1278 - 1281. [Abstract] [Full Text] [PDF]

				E. D. Wigle, L. Schwartz, A. Woo, and H. Rakowski To ablate or operate? that is the question! J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1707 - 1710. [Full Text] [PDF]

				D.-S. Lim, R. Roberts, and A. J. Marian Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1175 - 1180. [Abstract] [Full Text] [PDF]

				U. Sigwart Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy Eur. Heart J. Suppl., October 1, 2001; 3(suppl_L): L38 - L42. [Abstract] [PDF]

				F. Somura, H. Izawa, M. Iwase, Y. Takeichi, R. Ishiki, T. Nishizawa, A. Noda, K. Nagata, Y. Yamada, and M. Yokota Reduced Myocardial Sarcoplasmic Reticulum Ca2+-ATPase mRNA Expression and Biphasic Force-Frequency Relations in Patients With Hypertrophic Cardiomyopathy Circulation, August 7, 2001; 104(6): 658 - 663. [Abstract] [Full Text] [PDF]

				Y. Takeichi, M. Yokota, M. Iwase, H. Izawa, T. Nishizawa, R. Ishiki, F. Somura, K. Nagata, S. Isobe, and A. Noda Biphasic changes in left ventricular end-diastolic pressure during dynamic exercise in patients with nonobstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., August 1, 2001; 38(2): 335 - 343. [Abstract] [Full Text] [PDF]

				S. F. Nagueh, S. J. Stetson, N. M. Lakkis, D. Killip, A. Perez-Verdia, M. L. Entman, W. H. Spencer III, and G. Torre-Amione Decreased Expression of Tumor Necrosis Factor-{{alpha}} and Regression of Hypertrophy After Nonsurgical Septal Reduction Therapy for Patients With Hypertrophic Obstructive Cardiomyopathy Circulation, April 10, 2001; 103(14): 1844 - 1850. [Abstract] [Full Text] [PDF]

				W. Mazur, S. F. Nagueh, N. M. Lakkis, K. J. Middleton, D. Killip, R. Roberts, and W. H. Spencer III Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy Circulation, March 20, 2001; 103(11): 1492 - 1496. [Abstract] [Full Text] [PDF]

				M. Kamisago, S. D. Sharma, S. R. DePalma, S. Solomon, P. Sharma, B. McDonough, L. Smoot, M. P. Mullen, P. K. Woolf, E. D. Wigle, et al. Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy N. Engl. J. Med., December 7, 2000; 343(23): 1688 - 1696. [Abstract] [Full Text] [PDF]

				B.J. Maron Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator Eur. Heart J., December 2, 2000; 21(24): 1979 - 1983. [PDF]

				E. H. C. Yu, A. S. Omran, E. D. Wigle, W. G. Williams, S. C. Siu, and H. Rakowski Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2219 - 2225. [Abstract] [Full Text] [PDF]

				M. V. Sherrid, D. Z. Gunsburg, S. Moldenhauer, and G. Pearle Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1344 - 1354. [Abstract] [Full Text] [PDF]

				B. J. Maron, I. Olivotto, P. Spirito, S. A. Casey, P. Bellone, T. E. Gohman, K. J. Graham, D. A. Burton, and F. Cecchi Epidemiology of Hypertrophic Cardiomyopathy-Related Death : Revisited in a Large Non-Referral-Based Patient Population Circulation, August 22, 2000; 102(8): 858 - 864. [Abstract] [Full Text] [PDF]

				W. H. Spencer III and R. Roberts Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy : The Need for a Registry Circulation, August 8, 2000; 102(6): 600 - 601. [Full Text] [PDF]

				P. Spirito, P. Bellone, K. M. Harris, P. Bernabo, P. Bruzzi, and B. J. Maron Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy N. Engl. J. Med., June 15, 2000; 342(24): 1778 - 1785. [Abstract] [Full Text] [PDF]

				S.-T. Li, C. J. Tack, L. Fananapazir, and D. S. Goldstein Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1867 - 1873. [Abstract] [Full Text] [PDF]

This Article Extract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wigle, E. D. Articles by Williams, W. G. Search for Related Content PubMed PubMed Citation Articles by Wigle, E. D. Articles by Williams, W. G. Pubmed/NCBI databases Medline Plus Health Information Cardiomyopathy